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ABSTRACT OF DISSERTATION

FRAILTY IN PATIENTS UNDERGOING LEFT VENTRICULAR ASSIST
DEVICE IMPLANTATION

Heart failure is a progressive condition that affects over 5.7 million Americans
and costs associated with heart failure account for 2-3 % of the national health care
budget. The high rates of morbidity and mortality along with increased costs from
readmissions associated with advanced heart failure have led to the exploration of
advanced treatments such as left ventricular assist devices (LVADs). LVADS have
demonstrated morbidity and mortality benefit but cost remains extensive with costs per
quality-adjusted years > $400,000. With this in mind, it is important to identify those who
are most likely to benefit from an LVAD to avoid unfavorable outcomes and cost.
Although general guidelines and criteria for patient eligibility have been established,
choosing patients for LVAD implantation remains challenging. A new focus on patient
selection involves the presence of frailty. While frailty has been studied in the elderly
population and in patients undergoing cardiac surgery, frailty in patients undergoing left
ventricular assist device (LVAD) remains controversial. The purpose of this dissertation
was to examine measures of frailty in patients undergoing LVAD implantation. The
specific aims of this dissertation were to: (1) identify a feasible frailty measure in adults
with end-stage heart failure who underwent LVAD implantation by testing the hypothesis
that frailty would predict 30 day rehospitalization rates using Fried’s criteria, Short
Physical Performance Battery test, handgrip strength, serum albumin and six minute walk
test (2) Determine whether frailty measures improve 3 months post LVAD implantation
(3) compare sensitivity of these three measures to change in frailty.
Surgical approaches, including heart transplantation and LVAD implantation, for
patients with end-stage heart failure was discussed in this dissertation. Data from two
subsets of participants who underwent LVADS at the University of Kentucky between
2014 and 2017 were included in the analysis for this dissertation. In the first study, we
found that none of the measures are good predictors of frailty in patients with advanced
heart failure who undergo LVAD implantation. Handgrip was the only marker of frailty
that predicted 30 day readmission but the relationship was a negative association. In the
second study, six-minute walk and low serum albumin levels reflect short-term

improvement in frailty. These simple measures may be used to determine those patients
who are responsive to LVAD implantation.
The findings of these studies filled some gaps in our understanding of markers of
frailty in patients undergoing LVADs. We gained a better understanding of which
markers of frailty are likely to improve in most people after LVAD implantation and thus
frailty should not preclude candidate selection for an LVAD. Subsequently, more
research is needed to investigate these markers and outcomes.
KEYWORDS: left ventricular assist device; frailty, six minute walk test, albumin, hand
grip strength
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Chapter One: Introduction
Heart failure is a progressive condition that affects 5.7 million Americans with
more than 670,000 new cases a year. Costs of heart failure care account for 2-3% of the
national health care budget.- Heart failure readmissions remain a burden with rehospitalization rates of 20% at one month and 50% at 6 months. Over 43% of patients
diagnosed with heart failure are hospitalized at least five times or more within 5 years of
being diagnosed. There has been very minimal improvement in survival with medical
treatment, particularly for patients with end stage heart failure with 1 year mortality in
such patients of 15-35%.
The high rate of morbidity and mortality, and poor quality of life associated with
heart failure has led to exploration of additional treatments for those with advanced heart
failure that include left ventricular assist devices (LVADs). There is a morbidity and
mortality benefit with use of LVADs, although the cost associated with their use is
extensive.- In addition to fixed cost from the LVAD, which is greater than $100,000,
LVADS may result in complications, such as bleeding and infection, that contribute to
increased cost due to re-hospitalization, treatment and prolong hospitalization.
For the past decade, improvements have occurred in device technology, patient
selection and postoperative management, which have led to decreased cost but despite
these advances, costs per quality-adjusted years is still >$400,000. Iyengar et al examine
the relationship between length of stay and cost and demonstrated that in the LVAD
population, a 25% decrease in average length of postoperative stay was associated with a
40% decrease in average costs. They also reported that complications such as bleeding,
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respiratory failure and infections after LVAD implant were associated with increased cost
of $20,000-$50,000.
In order to gain better insight into to the expenses associated with complications
associated with LVAD implantation, a multidisciplinary team approach was incorporated.
This additional focus not only examined risk factors associated with complications,
which includes hypotension, inotrope requirements, obesity and RV dysfunction, but also
included physical therapy and nutritional assessment. By providing more focus on patient
education in regards to physical and nutritional needs and risk factors associated with
complications, a reduction in cost associated with LVADs was noted.
With this in mind, it is important to investigate factors that could potentially
decrease further cost and complications without compromising treatment outcomes. One
possible way which expands on the study posed by Iyengar et al is to consider whether
the patient meets criteria for frailty that could be addressed before or during
hospitalization. Many elderly heart failure patients, especially those who are hospitalized,
are frail. Frailty has been identified as an important prognostic marker for adverse
outcomes including death, disability and re-hospitalization. - Thus, identifying patients
with frailty while they are hospitalized may promote intervention to manage frailty and
its consequences, thus decreasing cost.
Frailty is a construct that includes assessment of physiological insults across
many organ systems that result in increased vulnerability to physical and psychological
stressors. - While a few investigators have examined the relationship of frailty and
outcomes of advanced heart failure patients, no one has examined the relationship
between frailty and hospital length of stay and readmissions in patients who receive an
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LVAD.- The purpose of this dissertation is to determine markers of frailty in patients
undergoing LVAD implantation and the association of pre-operative frailty with postoperative frailty on length of stay and re-admissions and to determine whether the
components of frailty are stable or whether they change after LVAD implantation.
In the second, third and fourth chapters of this dissertation, I examine how endstage heart failure is treated with LVADs. In addition, I examine how frailty impacts
length of stay, 30 day readmissions and if frailty improves 3 months after LVAD
implantation. I also compare my proposed markers of frailty to an existing model to
determine if the measurements are similar. The final chapter of the dissertation
summarizes the findings of the previous chapters and bridges gaps in current research.
End-Stage Heart Failure
Heart failure currently affects more than 5.7 million Americans and more than 26
million people worldwide and attributes to substantial costs of more than $30.7 billion
annually. It is estimated by 2030 that heart failure will affect more than 8 million adults
in the United States and costs associated with heart failure will continue to increase to
exceed more than $69.7 billion., A majority of cost are attributed to frequent
hospitalizations as the disease progresses toward end-stage heart failure. More than 43%
of patients are hospitalized more than 5 times within 5 years of being diagnosed. It is
estimated that approximately 5-10% of patients with heart failure are end stage or stage D
and have persistent symptoms despite guideline-directed medical therapy (GMDT)
resulting in more frequent hospitalization. Approximately 15-35% of patient with end
stage heart failure have a1 year mortality.,
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Once diagnosed with heart failure, patients are placed on GMDT in an attempt to
not only provide symptom relief and prevent hospitalizations, but also improve mortality
and decrease the risk of major cardiovascular events. As the disease continues to
progress, more definitive treatments for end-stage heart failure should be considered. Due
to disease severity, limited therapeutic options are available including inotropic support,
cardiac transplantation or left ventricular assist device (LVAD).
The American College of Cardiology/American Heart Association and the Heart
Failure Society of America recommend continuous inotropic support for the treatment of
advanced heart failure to patients who have failed GMDT in an attempt to improve
quality of life and reduce symptom burden.- Inotropic support may be used to stabilize
patients as a bridge to cardiac transplant or mechanical support, or discharge home.
Patients initiated on inotropic support require close monitoring due to the potential of
symptomatic hypotension, life-threatening arrhythmias or worsening renal dysfunction.
While inotropic support may provide symptom relief, there is no mortality benefit
and 1 year survival rate on inotropic support is approximately 10-15%., For patients who
are discharged home on inotropic support, palliative care should be involved to assist
with end of life care as they start to fail inotropic support. For those who are on inotropes
as a bridge therapy, close monitoring for signs of deterioration is crucial for timing of
surgical intervention.
Definitive surgical intervention for end-stage heart failure includes ventricular
assist device or cardiac transplantation. Heart transplant remains the preferred treatment
of end-stage heart failure with an estimated survival rate of 90%. However, in the United
States the number of people waiting for a heart transplant continues to increase and is
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approximately 3,805 which is a 25% increase over the past decade. The number of
donations remains stable around 3.5 per 1000 deaths and wait times continue to increase.
Due to donor shortage, mortality on the heart transplant wait list is high with
approximately 10% of patients dying per year while waiting for a heart transplant., ,
LVADs are increasingly being utilized in patients with end stage heart failure to bridge
patients to heart transplant and as destination therapy for those who are not transplant
candidates.
LVADs were originally designed as a bridge to cardiac transplants but have evolved
to include destination therapy for treatment of end-stage heart failure in those who meet
eligibility requirements. The Randomized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure trial established the use of LVADs as a treatment
for patients with end stage heart failure and reported a 48% reduction in death from any
cause. LVADs have an estimated 1 year survival of 89% and over 68% report improvement
in quality of life. Additionally, over 77% of patients implanted with LVAD report
improvement in NYHA class., ,
Left Ventricular Assist Device
The rise in the healthcare budget and increased incidence and prevalence of heart
failure has led to the exploration of advanced therapies for heart failure to improve
treatment outcomes and decrease cost associated with this devastating disease. As heart
failure progresses, the addition of continuous intravenous inotropic support, such as
dobutamine and milrinone, may improve clinical outcomes, but is associated with a poor
survival rate at 1 year of 10-30%. These patients have diminished functional status, poor
quality of life and have frequent readmissions. Only a minority of patients are eligible for
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heart transplantation, and of those, many will not receive a transplant because of the
limited supply of donor hearts. This situation leaves a substantial number of patients with
limited options. The addition of LVADs as an adjunct to traditional medical treatment for
heart failure patients who require advanced therapies to improve long-term survival is
gaining acceptance., , ,
LVAD is a type of implantable mechanical circulatory support that assist the
native left ventricle. It consists of internal and external components that work to increase
cardiac output. The LVAD has an inflow cannula which is inserted into the left ventricle
and connects to a pump, which is connected to an outflow cannula that attaches to the
aorta. Blood is propelled by a rotor through the system into the aorta and systemic
circulation. The pump also has a driveline, which connects the internal pump to an
external power source.
LVADs which were originally used as a bridge to heart transplantation are now
approved as destination therapy in patients who cannot receive heart transplant or cannot
wait for a heart transplant. Randomized clinical trials have noted a 48% risk reduction of
death in LVAD patients compared to patients on medical therapy. In the USA, the
incidence of LVAD implantations has increased from 2006 to 2010 from 206 to 1451
while the number of heart transplants remains unchanged. According to the 2014
ITERMACS registry 3500 continuous flow-LVADs (CF-LVADs) were implanted in
2013, while the number of heart transplants remains around 2200 implants per year in the
US. In addition, hospital cost associated with heart failure improved over the last 10 years
as the number of LVAD implants increased with approximately $14,000 or 3.6% per
patient.,
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While the overall survival of patients on CF- LVADs has an increased at 1 year to
85% (HeartMate II) and 92% at 6 months (HeartWare), the CF-LVAD is not without
burden. Although the implantation of CF-LVAD is considered safe and effective, adverse
events with CF-LVADs can lead to poor outcomes and re-hospitalization. The most
common complications associated with second generation CF-LVAD include bleeding
and infection.
Gastrointestinal (GI) bleeding is the most common complication and cause of rehospitalization in patients with CF-LVAD. The incidence of GI bleeding in patient with
CF-LVADs is between 18.9% and 22.3%. Risk factors for GI bleeding in patients with
CF LVADs included older age (20.5 x greater risk of bleeding) and chronic renal
insufficiency.GI bleeds in patient with CF-LVADs stems from a combination of factors
including anticoagulation, anti-platelet therapy, Von Willebrand disease, impaired
platelet aggregation and formation of arteriovenous malformations in the GI tract., When
CF-LVADs are implanted, a non-biological surface is placed in the body. Blood flows
over this surface, which predisposes the blood to clotting. To reduce the incidence of
clotting, there is a need for anticoagulation. CF-LVADs require anticoagulation with
warfarin, which increases risk of bleeding. Nearly all patients who experience GI
bleeding have therapeutic or subtherapeutic INRs at the time of bleeding suggesting that
antithrombotic therapy alone does not account for higher bleeding rate in patients with
CF-LVADs., ,
Physiological changes related to the lack of pulsatility also contribute to increased
rate of GI bleeding in patients with CF-LVADs. Native hearts create pulsatility, which
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results in pressure and flow changes. The human cells detect and adapt to these changes.
Pulsatility results in shear and strain forces on the endothelium, smooth muscle and
fibroblast cells in the circulation which in turn results in vasodilatation and vascular
remodeling.- Without pulsatility, the normal processes do not occur. Instead there is a
thinning of the vasculature, decreased bradykinin-dependent vascular relaxation. There is
also increased vascular oxidative stress which results in degradation of vascular cell
proliferation. This results in angiodysplasias, which attribute to approximately 55% of
bleeding lesions in patients with CF-LVADs.Acquired von Willebrand syndrome has also been noted to be a common cause of
bleeding in patients with CF-LVADs. Von Willebrand factor is necessary for platelet
aggregation. When the blood passes through the pump, shear stress disrupts multimers
associated with factor VIII, which leads to acquired von Willebrand deficiency resulting
in coagulopathy.While the etiology of GI bleeding is found in over 70% of cases by upper
endoscopy or capsule endoscopy, GI bleeding continues to be problematic in patients
with CF- LVAD and treatment of GI bleeding is essential to lowering healthcare cost
associated with readmissions. Few investigators have examined medications to assist with
preventing or slowing GI bleeding in patients with CF-LVADs but all of these
medications are still under investigation and attribute to significant costs. Additional
factors that can decrease cost associated with GI bleeds need to be examined and studied.
As the number of LVAD implants increase, complications of device related
infection emerge. Approximately 17% of patients with LVADs develop infection within
the 1st year post-implant and the risk increases to 33% and 45% at 3 and 5 years
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respectively. One of the most common infections associated with LVADS is driveline
infection with a rate of 7%, 20% and 29% at 1, 3 and 5 years respectively. Patients are at
risk of developing driveline infection due to a percutaneous driveline that extends from
the internal pump, out the skin, to an external energy source. Most driveline infections
are at the driveline exit site and if untreated, travel up the driveline to the pump resulting
in a pump pocket infection. Once a patient has a pump pocket infection, the risk of
bacteremia and sepsis increase. As a result, patients are often hospitalized due to the
complexity of medical care and require extensive, long-term antibiotic coverage and 70%
require surgical revisions which results in substantial cost.- Infection associated with
LVADs contributes to 41% of deaths.
Due to the expense associated with readmissions, increased length of stay,
morbidity and mortality associated with infection, researchers have focused on factors
linked to increased risk of infection post-LVAD. Heart failure patients are already at
higher risk of morbidity and mortality due to nutritional disorders, cachexia, and being
overweight. These same co-morbidities are being examined in patients with LVADs.
Nutritional factors such as low albumin are associated with increased post-surgical risk of
infection and research has demonstrated that low albumin levels and BMI are
independent predictors of readmission due to drivel line infection., Research regarding
BMI is controversial. Some research supports that BMI is not a relevant factor in
determining post-operative risk associated with infection while other studies support that
overweight and obesity contribute to increased risk of infection post LVAD., , ,
Readmissions due to these complications is common and results in a significant
percentage of health care costs in this population. While the overall cost-effectiveness of
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treatment with an LVAD continues to improve, 5 year cost is estimated at $360,000. To
minimize expense associated with complications post VAD and re-hospitalization, it is
necessary to investigate factors or ways to decrease cost. One such way is to focus on
patient selection prior to LVAD implant. Patients with advanced heart failure already
have a wide range of comorbidities that can lead to unplanned hospital readmissions and
increased length of stay and this risk increases after LVAD implantation. These patients
are at increased risk of poor baseline health status, function decline and decreased quality
of life, all of which are predictors of mortality., While previous research has focused on
reducing hospital cost and readmissions due to bleeding and infection, a new focus on
patient selection prior LVAD implantation, which has extensively been studied in other
populations, is frailty.
Overview of Frailty
Frailty is an evolving concept that is gaining interest in a variety of populations.
Over 6 million people in the United States are frail and this number is believed to be
underestimated. It is recognized as a prognostic indicator and is a risk factor for adverse
clinical outcomes including mortality and prolonged hospitalization.- Approximately 45%
of patients who are frail have a 1 year mortality rate. In addition frailty is also predictive
of falls, institutionalization and is independently associated with post-operative
complications.
Frailty is a complex syndrome that affects many organ systems as a result of
stressors in the setting of a vulnerable state. Many suggestions have been proposed to
define frailty, but no formal definition has been recognized due to the complexity of the
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syndrome and inconsistencies in measurement. In this dissertation, I will define frailty in
the following section.
Frailty has extensively been studied in the community dwelling geriatric
population, and more recently has been investigated in patients with cardiovascular
disease and patients undergoing cardiac surgery. , , , Studies suggest that frailty exists in
25%-50% of patients with cardiovascular disease, 7% of people age 65-75 years and 26%
of people over the age of 75 years. Frailty occurs in 65-75% of patients with heart failure
and is a significant predictor for frequent hospitalization. Patients who are frail have a
65% higher hospitalization rate than non-frail patients. In addition, frailty in patients with
cardiovascular disease have a 2 fold increase in mortality and women with coronary
artery disease (CAD) are more likely to develop frailty.,
Multiple studies have been examined to assess the prevalence of frailty in
community dwelling older adults with cardiovascular disease. The Cardiovascular Health
Study (CHS) (n=4735), Zutphen Elderly Men’s Study (n=420), Beaver Dam Eye Study
(n=2962) and French 3 City Study and Health ABC study (n=3208) and Women’s Health
and Aging Studies (n=670) all noted an association between frailty and cardiovascular
abnormalities., Older community dwelling women were noted to be at higher risk of
developing frailty compared to men and were more likely to develop CAD events. In
addition, CAD and stroke were at highest risk of developing frailty and frailty was
strongly predictive of long-term survival.
Outside of community dwelling adults, there have been few studies examining the
impact of frailty in older hospitalized adults. In a study by Purser et al, patients with
cardiovascular disease admitted to the hospital were noted to be frail which was
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measured by slow gait speed and have a fourfold increase in mortality over 6 months
(n=309)., Patients with heart failure are 54% more likely to be frail and frailty was more
predictive of mortality than New York Heart Association Class. Another study by Lee et
al focused on patients admitted after undergoing cardiac surgery noted that frailty was
associated with a 43% increased risk of post-operative complications, length of
hospitalization and inability to be discharged home. Frailty was also highly correlated
with 30 day, 1 year and 2 year mortality due to the patients having a decreased ability to
mobilize and ambulate which contributed to additional complications such as postoperative pneumonia and re-intubation. Approximately 50% of patients in this study had
frailty measured by gait speed.
Frailty is also pertinent to the development and prognosis of patients with heart
failure. The Health ABC study concluded that frailty correlated with a 30% higher risk of
developing heart failure., Patients with heart failure who are frail have a higher 1 year
mortality risk than those who are not frail (17% vs 5%) and have more hospitalizations
(21% vs 13%) and impaired quality of life. In addition, patients with frailty had
prolonged hospital length of stay. The CHS study supported previous findings that frailty
in heart failure patients is associated with functional decline and increase risk of
hospitalization.
Frailty has also been studied in patients undergoing cardiac surgery to predict
post-operative outcomes. The Frailty Assessment Before Cardiac Surgery (Frailty ABC)
noted a 46% incidence of mortality in patients with slow gait speed compared to a 6%
incidence in those with normal gait speed. Additional studies also noted that pre-operative
frailty was associated with post-operative mortality at 30 days and 1 year., In addition,
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frail patients were less likely to be discharged home and were more likely to need
rehabilitation.
To date, few investigators have examined frailty in patients who undergo LVAD
implantation. Their findings have provided conflicting data (Table 1.1). Three
investigators examined the association of frailty with an increased time to extubation.
Only one group of investigators found a significant association between frailty and longer
time to extubation. , - Five groups of investigators compared hospital length of stay, which
found conflicting results. Prolonged length of stay was reported in 2 groups and no
difference in hospital length of stay was noted in the remaining 3 groups., - Three
investigators examined short term mortality (less than 30 days) and found no difference
between frail and non-frail patients., , Additionally, seven groups of investigators
examined long term mortality and only one reported increased mortality associated with
frailty., , , - The most commonly used measurement tool for these studies was Fried’s
phenotype.
Handgrip strength is a marker of frailty in other populations. A study by Chung
et al noted that impaired handgrip strength correlated with global myopathy, higher
postoperative complication rates and increased mortality following LVAD implantation.
While this study did not examine frailty, Chung et al makes reference that measures of
skeletal muscle function, such as handgrip strength, are part of the frailty phenotype and
may have prognostic value in patients undergoing LVAD implantation.
No studies have focused on interventions that slow or improve frailty in both the
LVAD and non-LVAD population but some have focused on interventions that may
improve physical function. Studenski et al analyzed 9 large prospective studies and

13

found that for every 0.1 m/s increase in gait speed, there was a 10% improvement in
survival in patients with heart failure. Maurer et al discuss that there were some
improvements to physical function in patients 3 months post LVAD implantation but
frailty itself was not reversed. It was suggested that to better assess improvements in
frailty additional components such as nutritional support should be incorporated into the
assessment. A study by Fiatarone et al attempted to expand on this by adding nutritional
support to their program, which did support that a high intensity exercise training
improved muscle strength and noted improvement in mobility and gait speed. However,
even with nutritional intervention, the nutritional status remained compromised.
Due to the implications of previous research and statistics, it is important to focus
on ways to prevent or slow the progress of frailty. In order for this to be effective, one
must first understand the variables that result in frailty. Due to the complexity of frailty,
there is no standard definition, which makes it difficult to conceptualize. Various
attempts have been made to try and operationalize and define frailty. This will be
discussed in the following section.
Defining Frailty: Conceptual Framework
While it is well known that frailty is a predictor of poor prognosis, defining frailty
has not been established. Even identifying criteria for frailty has been difficult due to the
complexity of the syndrome. Most variables that affect frailty are commonly associated
with other co-morbid conditions and aging which makes it difficult to distinguish
between the attributes. Some conditions such as cardiovascular disease, stroke,
depression, obesity and osteoarthritis, share the same characteristics as frailty leading to
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the potential for misclassification. Disputes continue as to what criteria should be used to
define frailty due to the relationship of frailty with aging, disability and chronic disease.
Research proposes that frailty is caused by underlying processes separate from
aging, but these processes have similar manifestations as other conditions as mentioned
previously. Patients with frailty and other co-morbid conditions such as cardiovascular
disease, arthritis, depression, obesity often have chronic low-grade inflammation. After a
stressor event, there is further disruption of homeostasis, which results in a decline of
status due to increased circulation of inflammatory markers. This results in a “cascade of
events” in which musculoskeletal, nutritional and hormonal defects interplay resulting in
further inflammatory and hormonal response causing further decline., This cycle
continues resulting in changes to skeletal muscle, leading to profound muscle loss and
impairs the body’s ability to maintain and repair itself, which promotes further decline in
physical performance, mental status and malnutrition., While frailty may encompass the
resulting components of this cycle such as malnutrition, loss of dependence, decreased
gait, generalized weakness, weight loss, muscle loss and exhaustion it is difficult to
discern frailty from other underlying conditions., This supports the importance of further
defining and conceptualizing frailty for better understanding.
The concept of frailty is complicated by the lack of a consistent definition.
Several definitions of frailty are discussed in the literature. Some of the more frequently
used definitions of frailty define frailty as a “state of increased vulnerability to adverse
outcomes,” an age associated biological condition and a dynamic state affecting an
individual who losses function and a geriatric syndrome due to a decline in physiological
reserve., , , Frailty has become increasingly relevant due to increased risk for
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decompensation, adverse events, complications, mortality and functional decline and
finding ways to measure frailty is on the rise.,
Frailty is multi-factorial and includes deficits that accumulate throughout life.
Frailty encompasses several attributes including skeletal muscle mass loss, decreased
activity levels, poor endurance, decline in walking performance and decreased activities
of daily living., Several measures of frailty have been examined but due to variability in
definition, no standard measurement of frailty has been identified. Over 20 assessment
tools have been developed to measure frailty and more than 70 variables have been
examined in these models to assess frailty, yet there is no formally objective measure.
These instruments share common core items including slowness, weakness and physical
inactivity.
The most common measurement of frailty in patients with heart failure is the
frailty phenotype developed by Fried and colleagues (Table 1.1). The frailty phenotype
defines frailty as the presence of 3 or more of the following 5 physical indicators: low
physical activity, weakness (measured by hand grip strength), slow walking speed,
unintentional weight loss (>10 lbs in 1 year) and self- reported exhaustion., The Fried
scale has demonstrated to predict mortality and disability in community dwelling elders,
patient with cardiovascular disease, patients with heart failure and patients undergoing
cardiovascular surgery or procedures. Several modifications of the Fried scale have been
widely used to assess frailty in several substrates of population with over 200
modifications with physical activity and weight loss being modified most often., ,
While the Fried score is one of the most widely used measurements, some of the
individual components have been studied and are associated with frailty. Single item
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measures appear to be sufficient at assessing frailty and are more practical. Gait speed is
commonly used to measure frailty and is associated with a 3 fold increase in postoperative mortality and morbidity for patient undergoing cardiac surgery. In addition,
slow gait speed is associated with a 30% increase of hospitalizations in patients with
heart failure., Gait speed alone was also the most accurate predictor of 6 month mortality
in a study assessing frailty in patients with coronary artery disease., It is easily applicable
without much time or cost and doesn’t rely on subjective questionnaires. The patients use
little effort and walk comfortably.
Poor grip strength is also predictive of frailty and is used often due to patients not
being able to ambulate or being to deconditioned to perform other measures of frailty.
Handgrip strength correlated with operative risk in patients undergoing cardio-surgery, as
well as increased length of stay and was independently predictive of 30 year mortality.,
Handgrip strength was also noted to be predictive of disability and functional decline
over 25 years.
Another common measurement of frailty in patients with cardiovascular disease,
older adults and patients with heart failure is the Rockwood’s frailty index of multiple
deficits, also known as the deficit index. Measuring frailty through the deficit index
allows one to determine the severity of frailty through age associated health disorders
such as symptoms, diseases, disabilities. The index is associated with negative healthrelated outcomes including hospitalizations and mortality. This measurement is more
commonly used in community dwelling elderly population due to the ease of use. In
addition, the deficit index is more sensitive predictor of outcomes than Fried’s frailty
phenotype because it is a more sensitive measure of a patients vulnerability to stressors.
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While it is comprehensive, administration of the assessment is time consuming which
limits its use. Frailty is determined based on a calculated index. A Score 0.21 < FI < 0.45
= frail and FI > 0.45 most frail. This concludes that the frailer person is the more
vulnerable they are to adverse outcomes.
The CHS scale and the MacArthur Study of Successful Aging (MSSA) are
additional instruments used to measure frailty in patients undergoing cardiac surgery. The
CHS scale includes the 5 items of Fried’s Criteria: gait speed, weakness measured by
handgrip strength, physical inactivity measured by questionnaire, exhaustion measured
by questionnaire and unintentional weight loss > 10 lbs in 1 year. If three or more items
are positive, one is classified as frail. In addition, the CHS has several modifications
some of which have been expanded to include cognitive impairment and mood
disturbance. The MSSA also includes 5 items; cognitive impairment, self-reported
weakness, anorexia, high IL-6 and high CRP. Four or more items are required to be
deemed frail.
The Short Physical Performance Battery (SPPB) test is an instrument for
measuring physical performance in the aging population and has been used to measure
frailty. This measurement of frailty has also been extensively examined in older adults
with cardiovascular disease. The SPPB measures frailty by examining slowness,
weakness and balance. Three timed physical performance tests are performed: gait speed,
chair rises and tandem balance. Each is scored on a 0 to 4 scale and one is considered to
be frail if they have a total score < 5 of 12.
The SPPB has been identified as one of the best physical performance tests to
identify frail adults and is associated with disability and mortality. It has good concurrent
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validity when compared to other measures of frailty. Patients with lower SPPB score are
more likely to be disabled and have a higher mortality rate or re-hospitalization rate over
1 year. In addition, patients who had a score of 8 out of 12 had a significantly shorter
length of hospital stay compared to the subgroup with a score of 4 or less.
Multiple attempts at defining and conceptualizing frailty have been attempted, but
all populations are different and are affected by different variables, which makes it
difficult to generalize one specific instrument to measure all populations. In addition, it is
difficult to discern underlying conditions associated with co-morbid conditions and frailty
itself. A systematic review of the literature on frailty led to exploration of a new
conceptual framework to further define frailty in the LVAD population.
This conceptual framework (Figure 1.1) incorporates the most important
components of frailty in the LVAD population. A full understanding of the concept of
frailty in this population is necessary to understand how it impacts health outcomes.
Further definition of some of the variables of the concept were explored.
Malnutrition and weight loss
Patients with advanced chronic heart failure often experience progressive
unintentional weight loss, as a result of decreased appetite and malabsorption due to
gastro-intestinal congestion. Unintentional weight loss (> 10 lbs in on year) has been
shown to be associated with post-operative complications, prolonged hospitalization,
decreased survival and greater burden of morbidity and mortality in patients with heart
failure., Unintentional weight loss occurs in approximately 50 % of patient with heart
failure and approximately 15% of heart failure patients are found to have cardiac
cachexia.-
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Cardiac cachexia is a multifactorial metabolic and inflammatory response
associated with increased morbidity and mortality. Cachexia was a predictor of 18 month
mortality in patients who had percutaneous coronary intervention. Cardiac cachexia
occurs as a result of decreased absorption of nutrients through the gastrointestinal system
and increase metabolic demands leading to a catabolic state resulting in muscle wasting
which leads to further weight loss and malnutrition., , Inadequate nutrition is associated
with poor outcomes, increases length of hospitalization and results in postoperative
complications., Cardiac cachexia is a strong indicator for mortality in patients with heart
failure and when combined with low peak oxygen consumption, it identifies patients at
high risk of death. Some research supports more favorable outcomes with higher BMI
and survival, but there is limited data on the effects of weight loss on survival.
Due to the negative impact of cardiac cachexia and malnutrition on outcomes of
patients with heart failure, measures of nutritional status are being examined. One such
measure is by examining albumin levels. Low albumin levels < 2.5 mg/dl are associated
with increased morbidity and mortality in patients who have had general cardiac surgery,
as well as all cause mortality in older adults., , Hypoalbuminemia in heart failure patients
is also being examined. In the heart failure population, low albumin is due to
inflammatory stress, hepatic congestion and impaired protein syntheses. Albumin levels
are associated with higher NT-proBNP levels and worse NYHA status. Low albumin
levels decrease intravascular osmotic pressure of the capillary beds. This leads to loop
diuretic resistance due to a decrease of albumin-loop diuretic binding capacity. The
binding of albumin to diuretics is key for effective diuresis.
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Additional research has examined the relationship of low albumin levels and
BMI. Patients with serum albumin levels of less than 2.5 g/dl have an increased risk of
death and post-operative bleeding., In combination with a low BMI less than 20, these
patients were at increased risk of death, stroke and bleeding, while patients with BMI
over 30 had increased risk of arrhythmias and infection. An additional study by RappKesk also supported that patients with low BMI and low serum albumin levels were at
increased risk of death and infection post cardiac surgery.
Nutritional status has been studied in patient with heart failure through various
screening tools such as the Mini Nutritional Assessment Short Form, Nutritional Risk
Screening and the Prognostic Nutritional Index. These screening tools are complex and
subjective and an easy and more objective form of measuring nutritional status, via serum
albumin levels, is gaining acceptance. Serum albumin levels are an easy and objective
measure of nutritional status. As mentioned previously, serum albumin levels have been
well studied in the general cardiac surgery population and are associated with poor
outcomes and has also been studied as a predictor for survival in patient with heart
failure., , More recently, limited studies have examined low albumin levels in the LVAD
population. Low albumin levels (<2.5 mg/dl) are associated with morbidity and mortality
after LVAD implant and decreased survival. However, one study noted that low albumin
levels are corrected within six months after LVAD implantation. Further analysis of
albumin is needed before conclusions can be made regarding postoperative outcomes in
patients with LVADs.,
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Strength
Loss of muscle mass and changes in muscle metabolism are well known markers
of frailty in patients with cardiovascular disease, coronary artery disease and cardiac
surgery patients., In patients with heart failure, global myopathy results in decreased
strength. Hand grip strength is a marker of frailty that has been correlated to outcomes
and mortality in these populations. It is independently recognized as a predictor of
mortality and functional decline. Several frailty scoring systems measure handgrip
strength due to the ease of administration with minimal physical stress on patients. In
addition, it is measured by a dynamometer, which is relatively inexpensive and can be
tested in patients who are ambulatory and non-ambulatory. This is important for patients
with advanced heart failure due to severity of their illness resulting in deconditioning and
frequent hospitalizations. Most patients with advanced heart failure who are being
considered for LVAD are weak and cannot tolerate testing that results in stress.
While several studies in other populations have examined handgrip strength as a
measure of frailty and how it relates to outcomes, few studies have examined hand grip
strength as a measure of frailty in the LVAD population. Handgrip strength defined as at
least 25% of body weight was associated with decreased survival and increased
complications including bleeding and infection in patients undergoing LVAD
implantation., While patients in this study were thought to have more physical limitations
than patients in other studies, almost 1/3 of patients had noted improvement in handgrip
strength 6 months after LVAD implantation.
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Functional Capacity
Deterioration in skeletal muscle associated with advanced heart failure is
currently being studied. Changes in muscle fibers, decrease in type 1 fibers and increase
in type 2 fibers, occurs as a result of the metabolic demands associated with cardiac
cachexia, which results in a decline in functional capacity. In addition, these changes to
the muscle structure result in changes to muscle mitochondrial and enzymatic capacity
which are usually measured by VO2 max. Measuring peak oxygen consumption requires
complicated and expensive equipment. Most studies to date that are examining frailty
have assessed exercise capacity by measuring gait speed because it is a time and resource
efficient prognostic indicator of mortality., It has been well studied in other populations
and is associated with mortality, functional decline and increased operative risk.,
However, gait speed does not measure VO2 max, which leads to the assumption that the
6 minute walk test may be a more accurate predictor in patients with heart failure since it
has been established as a measure of aerobic capacity. The 6MWT best correlates with
maximal oxygen consumption compared to other measures and is easy to be
administered, well tolerated by patients and reflects daily activities. Several studies have
reported that the 6 MWT is a reliable measure of increased mortality and rehospitalization and is a strong indicator of poor prognosis in patients with heart failure.
Studies in patients with heart failure have demonstrated that the 6 minute walk
test is a valid measurement of functional capacity and have found an association with
mortality and outcomes., , Walking less than 300 meters is a predictor of increased
morbidity and mortality. Mortality was 3.5 times higher if subjects walked less than 350
meters than those walking over 450 meters. The 6 min walk test is a feasible measure in
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patients with heart failure and is already incorporated into routine care. The 6MWT also
encompasses may domains of physical function, which are part of the frailty phenotype.
A comparison between the 6 minute walk test and frailty using gait speed demonstrated a
high correlation between the two measures in patients with heart failure. Another recent
study reported that the 6 minute walk test was the strongest predictor of post- LVAD
survival. Further research is needed to understand how to best assist frail patients to
improved post LVAD implant.
This analysis of the concept of frailty provides a framework for the important
variables that contribute to frailty in the LVAD population and it was used in the studies
reported in this dissertation. It is important for the purpose of this dissertation that the
concept of frailty be efficiently defined, as there has been inconsistency in the literature
and has not been well studied in the LVAD population.
Gaps
This dissertation will fill some of the gaps in the literature by increasing our
understanding of how variables of nutrition, functional status, and strength result in
frailty. Many assessment tools and measurements of frailty have been well studied in
other populations but are not well known in the LVAD population. Part of the issue may
be that patients undergoing LVAD are critically ill and may not be able to participate in
some of the previously reported measures.
In exploring the influence of the different measurements of frailty, more research
is needed to examine and compare previously reported measures of frailty post VAD.
Current literature by Maurer et al notes that handgrip strength and gait speed improved 6
months post LVAD implant but weight loss is resistant to change which contradicts
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previously reported research supporting that LVAD implantation results in weight gain.
The study was small and did not provide meaningful results of frailty on length of stay
and survival. Most studies have also focused on older adults (> 60) which limits
generalizability of the previous studies. With LVADs increasing as destination therapy
and bridge for transplant, a wider age range needs to be examined. In addition, while
some assessment tools examine physical capabilities and nutrition as markers or frailty,
further studies are needed to assess if interventions are beneficial in slowing or
preventing frailty in these areas prior to procedures and surgery. Additional research is
needed to assess whether any markers of frailty will predict or effect current standards for
patient selection.
Summary of subsequent chapters
The impact of frailty on outcomes and rehospitalization in patients who receive
LVADs was studied in this dissertation. I explored markers of frailty in this population.
The variables discussed in this conceptual framework were used to guide the study,
designs, data collection, data analysis and interpretation of the results.
Chapter two was the discussion of surgical approaches to patients with end stage
heart failure. This chapter was important because it discussed the pathophysiology of end
stage heart failure and surgical approaches including heart transplantation and LVAD as
treatment options for this population. This is important because it provides the
background on how patients are selected for LVADs. Patients undergoing LVAD
implantation have to meet criteria to qualify for candidacy but additional conditions such
as frailty should also be considered to select patients who will benefit from implantation.
Patients with LVADs are at increased risk of complications post LVAD, rehospitalization
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and increased health care cost associated with these complications and it is important to
gain a better understanding to improve patient selection for LVADs, reduce readmissions,
reduce hospital cost and decrease hospital length of stay.
Chapter three was the report of a study in which markers of frailty included in the
proposed conceptual framework to define frailty was compared to previously reported
markers of frailty which include Fried’s criteria, SPPB, 6MWT, Albumin and handgrip
strength. This study was important because it established if markers of frailty included in
the proposed conceptual framework are appropriate markers of frailty in patient
undergoing LVAD implantation.
Chapter four was the report of a study conducted to determine whether frailty
improved 3 months post LVAD. This is important because only one study to my
knowledge have examined frailty post LVAD. A study by Maurer et al reported that
frailty measured by the Fried frailty criteria, decreased in approximately half of patients 6
months after receiving LVAD support. This study was important as it lays the ground for
future research to assess how improvements in frailty impact readmissions, length of stay,
complications post LVAD and cost post LVAD.
Chapter five is the integration of the previous chapters. It provides further
explanation of the link between the different variables of frailty and how they impact
outcomes. The comparison between variables and outcomes was further explored.
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Table 1.1: Frailty in LVADs
Author
Joseph 2017

Sample
Size (n)
75

Jha 2017

77

Mangehelli 2014

45

Cooper 2017

2469

Heberton 2016

100

Dunlay 2014

99

Sundararajan
2016

154

Fan 2017

50

Outcome
Measurement
-Time to
extubation
-Hospital LOS
-Short Term
Mortality
-Long Term
Mortality
-Time to
extubation
-Hospital LOS
-Long Term
Mortality

Results
-Significant
-Significant
-Not
significant

-Hospital LOS
-Long Term
Mortality
-Short Term
Mortality

-Not
significant
-Not
significant
-Not
significant
-Not
significant
-Not
significant
-Not
significant
-Significant
-Not
significant
-Not
significant
-Not
significant
-Not
significant
-Significant
-Not
significant

Long-Term
Mortality

-Not
Significant

-Time to
extubation
-Short Term
Mortality
-Hospital LOS
-Long Term
Mortality
-Hospital LOS
-Long Term
Mortality
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Frailty
Measurement
Fried Score

Fried Score

Fried Score

Provider
assessed frailty
and gait speed
Sarcopenia

Deficit Index >
0.25
Cachexia > 10
kg weight loss or
absolute BMI <
20
Fried Score

Table 1.2: Review of most common assessment tools for frailty
Frailty Measure
Criteria
Determinants of Frailty
Fried Criteria
5 Criteria; Unintentional
Positive 3 of 5 phenotypic
weight loss of > 10 lbs in
criteria
one year; Weakness
measured by handgrip
strength; Exhaustion that
was self-reported Slowness
measure by gait speed; Low
physical activity selfreported
Deficit Index
Cognitive status; Mood and Has at least 30 assessed
motivation;
health variables
Communication; Mobility;
Balance, Bowel function,
FI = Deficits
bladder function; ADLs;
n- missing values
Needing help from nutrition
or social resources; Number FI < 0.10 nonfrail
of comorbidities divided by
0.21 < FI < 0.45 Frail
2
FI > 0.45 most frail
Gait Speed
Time to walk 5 meters
Time to walk 5 meter > 6
seconds
Handgrip
Handgrip measured with
HGS < 85% normal
hand dynamometer
Short Physical
Gait speed; Time taken to
Each is scored on a 0 to 4
Performance Battery
stand from sitting in a chair scale: frail if they have a
5 times without using arms; total score < 5 of 12
Tandem balance
Comprehensive
Handgrip Strength; Gait
HGS < 85% normal; > 6
Assessment of Frailty
Speed; Activity level;
seconds to walk 5 meters;
Standing balance; Body
Questionnaire regarding
control
IADLs to calculate weekly
kcal expenditure; Standing
balance assessed by
amount of time individuals
could stand with both feet
together, semi-tandem, full
tandem and make a 360
degree turn; Body control
assess by time individuals
could get up and down
from chair 3 times, pick up
a pen from floor and put on
and remove a jacket
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Table 1.2, continued
Frailty Staging System

Disability; Mobility
disability; Cognitive
impairment; Visual
Impairment; Hearing
impairment; Total urinary
incontinence

Canadian Study of Health
and Aging Clinical Frailty
Scale

Disability: loss of > 1
BADL, Mobility
inability to do
housework, Cognitive
by mini-mental status
exam; 0-1 impairments
= class 1
2-3 impairments = class
2
4-7 impairments = class
3
Assess by a physician,
nurse, physiotherapist
and occupational
therapist

Very fit (regular exercise);
Well (no active disease);
Well (with treated disease);
Vulnerable (complain of
being slowed by disease);
Mildly frail (limited
dependence for ADLs);
Moderately frail (limited
dependence for ADLs and
IADLS); Severely frail
(complete dependence for
ADLs and IADLs or
terminally ill)
Cardiovascular Health Study 5 items: gait speed,
Presence of 3 or more
weakness measured by
handgrip strength, physical
inactivity measured by
questionnaire, exhaustion
measured by questionnaire
and unintentional weight
loss > 10 lbs in 1 year
MacArthur Study of
5 items; cognitive
4 or more items deem
Successful Aging
impairment, self-reported
frailty
weakness, anorexia, high IL6 and high CRP.
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Figure 1.1: Conceptual framework of frailty in patients with heart failure
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Chapter Two: Surgical Approaches in Heart Failure
Introduction
Heart failure is a progressive condition that continues to rise in both incidence and
prevalence accounting for more than 2-3% of the national health care budget.- Despite
improvements in treatment for end stage heart failure, the costs per quality-adjusted years
is still greater than $400,000. The high rate of morbidity and mortality associated with
advanced heart failure has led to exploration of additional treatments, which include
surgical interventions to improve outcomes.- This article will focus on the most common
surgical interventions that have demonstrated improvement in morbidity and mortality for
patients with heart failure.
Epidemiology of HF
The epidemiology of heart failure has been extensively studied for the past several
decades with a large contribution of literature stemming from the Framingham Heart
Study. Major findings in the 1980’s noted that heart failure increases with age, is higher
in men that women. In addition, hypertension, coronary artery disease and diabetes
mellitus are associated with increased risk of heart failure. In the 1980’s the prevalence of
heart failure was 24 per 1,000 in men and 25 per 1,000 in women with a median survival
time of 1.7 years in men and 3.2 years in women.
Longitudinal analysis of the Framingham Study noted in the 1990’s that heart
failure continued to rise in incidence and prevalence affecting about 1% of persons in
their 50’s with progressive increases to about 10% of persons in their 80’s. The incidence
also increased with age from 0.2% in persons 45 to 54 years to 4% in those 85 to 94
years. Mortality was noted to be around 37% within 2 years of diagnosis., , ,
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Continued analysis of epidemiologic data from the Framingham Study in the
2000s further supported the burden of heart failure effecting over 5 million Americans
with more than 550,000 new cases a year., Median survival was noted to be similar for
men and women as in the 1990’s with a 5 year survival rate of 25% of men and 38% of
women. Hypertension was noted to have the largest impact on heart failure, followed by
myocardial infarction, valvular heart disease and diabetes., ,
At present, heart failure affects more than 5.7 million Americans with more than
670,000 new cases a year. Readmissions related to heart failure continue to remain a
burden with rates of 20% at one month and 50% at 6 months with more than 43% of
patients being hospitalized more than five times or more within 5 years of being
diagnosed. Heart failure related admissions account for 56.7% of all heart failure
episodes with heart failure, with heart failure being the most common reason for
hospitalization in adults aged 85 years and older and the second most common for adults
aged 65- 84 years.- Approximately 15 to 35% of patient with end stage heart failure have
a 1 year mortality. Hypertension and diabetes remain the top co-morbidities linked to the
high prevalence of heart failure. ,
Pathophysiology of systolic HF
Heart Failure is defined as “a complex clinical syndrome that results from any
structural or functional impairment of ventricular filling or ejection of blood”. This
condition can ultimately lead to decreased exercise tolerance as well as symptoms of
dyspnea at rest and/or exertion as well as fatigue and edema with variable severity.
However, premise of heart failure physiology is increased intracardiac filling pressures,
which is further explained in the following section.
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Although there are two basic verities of heart failure, systolic as well as diastolic,
this article focuses on systolic heart failure. Systolic heart failure whether treated
according to guideline directed approach or not, ultimately leads to advancement of
myocardial dysfunction with end-organs being affected, which brings up the concept of
advanced heart failure. This entity is associated with refractory heart failure symptoms
despite medical therapy as well as persistently elevated intracardiac filling pressures,
inability to exercise as well as recurrent hospitalizations, which in turn is associated with
increased mortality. At this stage there are further options in treatment of heart failure
such as inotropic support but inevitably surgical approach such as heart transplant as well
as mechanical circulatory support.
Strength of myocardial contraction has been shown to be related to the preload
and thus the stretch of the fibers, which was first described by Otto Frank in 19th
Century. This finding was elegantly confirmed a century later by Ernest Starling and
colleagues where they have shown that increasing venous return and subsequent filling of
heart chambers increased stroke volume. Thus a principal described by “the ability of the
heart to change its force of contraction and therefore stroke volume in response to
changes in venous return and subsequent chamber filling pressure” came to be known as
Frank–starling principle. This is illustrated in Figure 2.1.
Note the myocardium does not operate on the single Frank-Starling curve but
rather its function as defined by multiple curves, as noted in Figure 2.2. These curves
represent myocardial physiology based on its afterload as well as inotropic state as
illustrated in Figure 2.2.
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In order to improve the understanding of heart failure pathophysiology, it is
important to understand frank starling curve, its principal of preload and how this
correlates with intracardiac filling pressures and thus the concept of pressure volume
loops.
Looking at the Frank Starling curve, we can visualize the effects of increased
preload in the form of left ventricular end-diastolic pressure (LVEDP) on the stroke
volume. In a normal functioning heart the higher the LVEDP the higher the stroke
volume with the curve theoretically not reaching its plateau as illustrated by Figure 2.1.
In contrast, increased inotropy increases the slope of this line, making the myocardium
more responsive and sensitive to preload with higher rate of stroke volume increased to
the amount of preload increase as denoted by line B in Figure 2.2. Decreased inotropy, as
in heart failure, appears to reach a plateau point of the curve at lower LVEDP, as
represented by line C in Figure 2.2.
To further visualize this principle, looking at pressure-volume loops becomes
evident when venous return is increased, there is increased filling of the ventricle leading
to an increase in end-diastolic volume (see Figure 2.3). If the ventricle now contracts at
this increased preload the ventricle empties to the same end-systolic volume, thereby
increasing its stroke volume, which is defined as end-diastolic minus end-systolic
volume, provided that the afterload and inotropy are held constant. The increased stroke
volume is displayed as an increase in the width of the pressure-volume loop. The normal
ventricle, therefore, is capable of increasing its stroke volume to match physiological
increases in venous return. This is not, however, the case for ventricles that are in failure.
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In a failing heart and thus systolic dysfunction, there is evidence of downward and
rightward shift of the Frank-Starling curve indicating loss of inotropy with resultant
increase in left ventricle (LV) filling pressures. Initially there are multiple compensatory
mechanisms in place to maintain stroke volume such as increased preload associated with
neurohormonal upregulation and retention of Sodium leading to increased blood volume
and thus increased filling pressures. Subsequently, these compensatory mechanisms
result in chamber remodeling manifested by dilatation, which initially is in essence
another compensatory phenomenon. This remodeling ultimately leads to decreased stroke
volume and persistently elevated filling pressures and volume overload. These
physiologic phenomena are illustrated in Figure 2.4.
Principle of treating advanced heart failure
The premise of treating heart failure is through control of congestion and thus
preload as it has been shown that the predominant majority of symptoms and recurrent
hospitalizations in heart failure patients are related to congestive exacerbation. In
addition, an important concept in treating heart failure is through controlling afterload.
This in turn can be achieved through neurohormonal blockade, which ultimately leads to
decrease in intracardiac filling pressures. - The strategy of achieving neurohormonal
blockade through medical therapy by utilizing the combination of angiotensin-converting
enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) with beta-blockers
(BBs) as well as more recently angiotensin receptor–neprilysin inhibitor, have reached a
Class I recommendation by the ACCF/AHA/HFSA.
Luckily for those patients refractory or intolerant to guideline directed medical
therapy, clinicians are now able to either replace the organ completely or support it with
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implantable pumps. Replacing the organ improves the physiology drastically but holding
true to the hemodynamic principle of heart failure the premise of treatment is to offload
the heart decreasing intracardiac filling pressures through decreasing volume overload
and improving the Frank-Starling forces such that it restores the pressure-volume loop
position to the right, with concomitant improvement in stroke volume.
Surgical Options
Heart Transplant
Despite advances in pharmacological as well as device therapy for chronic
systolic heart failure, long-term morbidity and mortality remain unacceptably high. Fiveyear mortality rate for patients with advanced heart failure is about 80% and thus further
surgical approaches are necessary. One of those options and a gold standard treatment of
advanced end-stage systolic heart failure is heart transplant. The fundamental indication
for heart transplantation is poor quality of life as well as rapidly progressive physiology
such as cardiogenic shock.
Since the first orthotropic, inter-human heart transplant performed on December,
3rd, 1967, at the Groote Schuur Hospital, in Cape Town, South Africa by Dr. Christian
Neethling Barnard, great progress has been made. By end of 1968, 102 transplants were
made in 17 countries and 52 centers. Only a third of these patients lived longer than three
months. It was not until 1980 with the dictation of cyclosporine, borrowed from renal
transplant, that ultimate successful progress resulted in improved survival. To date,
worldwide, about 3,500 heart transplants are performed annually. The vast majority of
these are performed in the United States (2,000–2,300 annually) with an average 1 year
survival rate of 90% with conditional half-life of 13.2 years. , , Heart transplant remains
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to gold standard of advanced heart failure treatment for carefully selected patients. Box 1
summarizes indications and contraindications for heart transplant.
Surgical Considerations
Orthotopic placement (organ placed in the anatomically original position) is the
most commonly utilized placement of donor heart during surgery. There are two main
techniques of anastomosing the recipient vasculature/structures to the donor heart:
Bicaval as well as Biatrial techniques. Biatrial technique represents the most widely
utilized approach to orthotropic heart transplant although this really depends on the
transplant surgeon. Figure 2.5.
Medical Considerations
As noted in Figure 2.6, early graft failure over the first year is the most common
cause of post transplant complications, including death. Graft failure downtrends with the
first year primarily due to acute rejection while infectious complications associated with
aggressive immunosuppression begins to take the stage during that time period.
Ultimately resurgence of graft failure as well as concomitant cardiac allograft
vasculopathy in addition to malignancy predominate long-term outcomes.
Mechanical Circulatory Support
Even though over the last 5 decades, heart transplantation has been the goal
standard of care for carefully selected patients with end-stage heart disease, challenges
continue to exist in this patient population. These challenges include complications
associated with post-transplant care, but more importantly increasing number of potential
recipient’s compared to the number of donor organs. Approximately 117,000 people need
a lifesaving organ. Every 10 minutes someone is listed for transplantation and every 22
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minutes someone dies while waiting for an organ. Because of this limiting factor, there
has been increase in technological advances in order to be able to keep patients with endstage, advanced heart failure alive in order to ultimately offer them the gold standard of
care. This technology being mechanical circulatory support, both short as well as long
term.
Interest in mechanical circulatory support (MCS) dates back to 1950’s during the
time of development of cardiopulmonary bypass and open-heart surgery. The first
successful implantation of a left ventricular assist device was completed in 1966 by Dr.
DeBakey. A paracorporeal (external) circuit was able to provide mechanical support for
10 days after the surgery. The lack of heart donors and contraindications to heart
transplantation further stimulated the necessity for development of this technology. The
first successful long-term implantation of an artificial LVAD was conducted in 1988 by
Dr. William F. Bernhard of Boston Children's Hospital Medical Center.
Initially pulsatile pumps were the standard of care given the thought that
pulsatility is a necessary physiologic phenomenon. Both Randomized Evaluation of
Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) and
Investigation of Non-Transplant Eligible Patients Who Are Inotrope Dependent
(INTrEPID) trials evaluated the role of pulsatile pumps in patients with advanced heart
failure who were ineligible for heart transplant and noted 48% reduction in mortality
compared with optimal medical therapy., The caveat and ultimately demise of pulsatile
pumps was their durability. Having a device which durability reaches about 24 months
could only serve as a prolonged bridge to transplant for patients who were too sick and
thus required implementation of mechanical circulatory support in order to improve end-
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organ function and finally be placed on heart transplant list. And thus how about the
patients who were not transplant candidates to begin with? Further endeavors with other
devices gave rise of continuous-flow pumps. In 1987 in a pediatric patient shed some
light in this regard when was implanted with a variation of continuous flow device as
bridge to transplant. Dr. Frazier, in his case report states that this procedure “prompted us
to speculate about broader application of nonpulsatile flow, to the development of fully
implantable devices for long-term cardiovascular support of the terminal heart disease
patient….The potential for long-term benefit lies in meeting the requirements of the
circulatory system with a nonpulsatile pump”. At the same time interests for more
durable devices has led to HeartMateII pump (a continuous-flow LVAD), replacing
pulsatile technology after a study showed that continuous flow LVADs improve survival
from disabling stroke and device failure as compared its predecessor (Heartmate XVE).
Currently all devices on the market are continuous-flow pumps based on axial or
centrifugal mechanism (See Figure 2.7). The axial-flow rotary pump consists of a
rotating, screw-like propeller within a tube housing. The energy from the rotating element
increases blood pressure and flow. The centrifugal pump with spinning blades captures
and throws fluid forwards, which results in essentially pulseless physiology, depending
on the residual left ventricular function. ,
Because temporary devices such as extracorporeal membrane oxygenation
(ECMO) will be discussed elsewhere in this issue, this section will focus primarily on
durable devices, namely LVADs as well as briefly discuss total artificial heart
technology. LVADs unload the left ventricle and thus, because of the fact that blood is
withdrawn directly from the left atrium (LA)/LV (considering there is no mitral stenosis),
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pulmonary capillary wedge pressure (PCWP) and LV EDP decrease. This is shown by
the Pressure-Volume (PV) loop left-ward as noted in Figure 2.8A. It should be noted that
although it appears that stroke volume decreases even though there is significant left
ventricular unloading as noted by the pressure volume loop, at the same time, arterial
pressure increases as noted in Figure 2.8B. Although peak LV pressure and arterial
pressure become increasingly dissociated compared to systemic, arterial blood pressure
significantly increased and thus ultimately improving end organ perfusion often resulting
in reversal of end-organ dysfunction. Figure 2.7B; Table 2.1.
Four major indications for LVAD implantation exist:
1.

Bridge to transplantation (BTT),

2.

Destination therapy (DT),

3.

Bridge to recovery, and

4.

Bridge to decision.

Indications and Contraindications for LVAD implantation are listed in Box 2.
Bridge to transplantation remains the most common indication for implantation of
LVADs. As mentioned earlier, due to the growing population of patients with advanced
HF and stagnant numbers of donor organs, improved durability of the newer devices
offers select patients increased survival and improvement of quality of life. This
ultimately may let those patients remain candidates for transplant later down the line.
Alternatively, destination therapy is offered to particularly selected patients with
advanced HF who are not candidates for heart transplantation (Figure 2.9).
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Temporary Options
Temporary Options are listed in Table 2.2.
Durable Options
There are basically two types of devices used: para-corporeal (percutaneous
ventricular assist device [PVAD]) and totally implantable (LAVDs or biventricular assist
devices (BiVADs)) (Table 2.3).
Total Artificial Heart
The first successful implantation of total artificial heart which led to subsequent heart
transplantation was performed in 1969. Subsequent successful implantations did not
occur until beginning of 1980. Since that time there are many models she had been
implanted but only one remains to be the most commonly utilized; SynCardiaTM TAH
(SynCardia Systems, Inc., Tuscon, AZ, USA) Figure 2.10. This particular device is
intracorporeal, pneumatically driven biventricular system, which completely replaces the
failing heart. The use of TAH as a bridge to transplant has demonstrated a 79% survival
to transplantation vs. 46% in patients not receiving a TAH in a small observational
prospective study. Box 3 summarizes indications and contraindications for TAH
implantation.
Surgical considerations
Because of the fact that human body generates a significant amount of scar tissue
around the device, reentry for future heart transplantation becomes significantly more
difficult. For this purpose the device itself as well as proximal vasculature are covered by
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a Gore-Tex material in order to facilitate future reentry and minimize necessity for
dissecting the structures.
Medical considerations
Most recent analysis of INTERMACS registry reveals that about 80% of people
are alive one year. Another analysis shows that survival to transplantation was 68.3%
with strokes occurring in 7.9% of the population.
Post implant management revolves around proper anticoagulation as well as
management of end organ dysfunction. The most common organs involved are liver
kidneys with renal dysfunction being related to lack of natriuretic peptides (ANP and
BNP). Level of post-operative end organ dysfunction is dependent on severity of
decompensated state prior to implantation.
Conclusion
Heart failure continues to increase in incidence and prevalence despite
pharmacological therapy and additional therapies such as cardiac resynchronization
therapy and remains the most common cause of hospitalization. Heart failure is
associated with poor quality of life and has an overall 1 year mortality rate of 20%. Due
to the morbidity, mortality and costs associated with heart failure surgical advances are
becoming more widely accepted.
Although heart transplantation remains the gold standard, organ availability
remains a major limitation. Due to the persistent donor shortage and increasing number of
patient with advanced heart failure, mechanical circulatory support is gaining acceptance
and can be used as a bridge to heart transplant for those eligible or as destination therapy.
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The current strategy for the management of advanced heart failure with reduced ejection
fraction (HFrEF) patients is to initially screen for heart transplant, with destination
therapy ventricular assist device considered as secondary treatment for those who do not
qualify for heart transplant. Regardless of which option is decided upon, the benefits of
heart transplantation or ventricular assist devices outweigh those of pharmacological
treatment of heart failure alone. Heart transplantation and ventricular devices improve
symptoms and survival in advanced heart failure with a 1 year survival of 90% compared
and should be considered in those who qualify.
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Table 2.1. INTERMACS Profiles
Level

Symptoms

Signs and Hemodynamics

Need for LVAD

1

"crash and
burn"

Critical cardiogenic shock,

Within hours

2

"sliding on
inotropes"

Progressive decline on inotropic
support

Within days

3

"dependent
stability"

Stable but inotropic dependent

Elective over weeks
to months

4

"frequent
flyer"

Resting symptoms although remains
home on oral therapy with frequent
hospitalizations.

5

Housebound

Exertion intolerant

6

"walking
wounded"

Exertion limited to symptoms,
although still responding to oral
guideline-directed medical therapy

Advanced
NYHA class II or III, responding to
7
NYHA III
oral guideline-directed medical
symptoms
therapy.
Abbreviation: NYHA, New York Heart Association

Variable urgency,
dependent on
nutrition and organ
function
Variable urgency,
dependent on
nutrition and organ
function
Variable urgency,
dependent on
nutrition and organ
function
Not currently
indicated

Table 2.2. Temporary Devices:
Device
Mechanism
Duration
IABP
Counterpulsation
Days
Impella
Axial Flow
Days
ECMO
Continuous Flow
Days to weeks
Centrimag
Centrifugal
Weeks
Tandem Heart
Centrifugal
Days
Abbreviations: ECMO, extracorporeal membrane oxygenation; IABP; intra-aortic
balloon pump.
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Table 2.3. Durable Devices:
Device
Mechanism
Indications
HeartMate II
Axial Flow
BTT, DT
HeartMate III
Centrifugal flow
BTT
HeartWare
Centrifugal flow
BTT, DT
TAH
Pulsatile
BTT
Abbreviations: BTT, bridge to transplant; DT, destination therapy; TAH, total artificial
heart.

Figure 2.1. Effects of Preload on Left Ventricular Filling Pressures and Ventricular
Function: Frank-Starling Principle

Abbreviations: LVEDP: Left Ventricular End Diastolic Pressure, SV: Stroke Volume.
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Figure 2.2. Frank-Starling graph to show effects of inotrope on stroke volume relative to
left ventricular filling pressures

A) normal contractility B) increased contractility C) Decrease contractility
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Figure 2.3. Pressure-volume loop as it relates to increased preload (venous return) and
left ventricular function (stroke volume).

Abbreviations: EDP: End Diastolic Pressure, SBP: Systolic Blood Pressure, DBP:
Diastolic Blood Pressure, AoV: Aortic Valve, LAP: Left Atrial Pressure, SV:
Stroke Volume.
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Figure 2.4. Pressure-Volume loop representing results of heart failure
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Box 1
Indications for Heart Transplant:
-

Significant life, limiting heart failure:
o Persistent NYHA class III or IV symptoms despite maximal guideline
directed medical therapy.
o decreased exercise tolerance (peak VO2≤ 14mL/kg/min for patients not on
beta blockers and peak VO2≤ 12mL/kg/min for patients on beta blockers).

-

Recurrent life-threatening LV arrhythmias despite optimized medical
antiarrhythmic therapy.

-

Refractory cardiogenic shock requiring mechanical circulatory support (LVAD,
TAH).

-

Cardiogenic shock requiring continuous parenteral inotropic therapy.

-

End-stage congenital heart patient with heart failure.

-

Refractory angina despite maximal medical therapy and not amenable to
percutaneous or surgical revascularization.

-

Severe hypertrophic or restrictive cardiomyopathy with end-stage heart failure
symptoms.

-

Severe cardiac allograft vasculopathy in transplanted patients with evidence of
graft failure.

Contraindications for Heart Transplant:
-

Age > 70 years old

-

BMI > 35 kg/m
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-

TPG > 15 mmHg, PVR > 5 Wood units or pulmonary artery pressure > 60 mmHg
with one of the above or the inability to achieve PVR < 2.5 Wood units with
vasodilator or inotropic therapy

-

Primary Lung disease with impaired pulmonary function tests (FEV1 < 40% or
predicted, FVC < 50% or normal DL < 40%)

-

Uncontrolled diabetes (HgbA1C > 7.5%)

-

eGFR < 30

-

Hepatic Cirrhosis

-

Severe peripheral vascular disease not amenable to revascularization

-

Active infections except LVAD related infections (HIV, Hepatitis B and Hepatitis
C)

-

Active drug use: must be abstinent 6 months

-

Non-compliance or lack of caregiver or social support

-

Dementia or mental retardation

Abbreviations: BMI body mass index, TPG transpulmonary gradient, PVR pulmonary
vascular resistance, FEV forced expiratory volume, FVC forced vital capacity, DLCO
lung diffusion capacity, HbA1C glycosylated hemoglobin, mmol millimoles, mol moles,
eGFR estimated glomerular filtration rate, mg milligrams, dl deciliters, HIV human
immunodeficiency virus, TB tuberculosis
(Data From Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society
for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update.
J Heart Lung Transplant 2016;35(!):1-23.
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Figure 2.5. (A, B) Two different approaches for anastomosis during orthotropic heart
transplant.
A
B

Biatrial Technique

Bicaval Technique

IVC: Inferior Vena Cava, SVC Superior Vena Cava, PA Pulmonary Artery
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Figure 2.6. Relative incidence of leading causes of death for adult heart transplants
(deaths: January 2009–June 2016). CAV, cardiac allograft vasculopathy; CMV,
cytomegalovirus; PTLD, post- transplant lymphoproliferative disorder.

(From Kirlkin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report:
special focus on framing the impact of adverse events. J Heart Lung Transplant
2017;36(10): 1080-6: with permission).
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Figure 2.7. The mechanism of axial (eg, HeartMate II) versus centrifugal (HeartWare,
HeartMate III) pump hemodynamics.

(From Lim HS, Howell N, & Ranasinghe A. The physiology of continuous-flow left
ventricular assist devices. J Card Fail. 2017;23(2):170; with permission.)
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Box 2
Indications for mechanical support:
•

Severe symptomatic heart failure despite optimal medical therapy

•

Left Ventricular Ejection Fraction (LVEF) that is less than or equal to 25 percent.

•

Exercise VO2 that is less than or equal to 12 ml/kg/min

•

Continuous intravenous inotropes or IABP therapy to prevent symptomatic
hypotension, decreasing renal function or worsening pulmonary congestion.

Contraindications for mechanical support:
•

blood clotting disorders

•

severe cirrhotic liver disease

•

severe lung disease

•

other co-morbid conditions that result in < 1 year survival

(Data From Miller LW, Guglin M. Patient selection for ventricular assist devices: a
moving target. J Am Coll Cardiol. 2013;61(12):1209-21.
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Figure 2.8. Flow-dependent changes of the pressure-volume loop

(A) Flow-dependent changes of the pressure-volume loop with LV-to-aortic pumping.
The loop becomes triangular and shifts progressively leftward (indicating increasing
degrees of LV unloading). Corresponding LV and aortic pressure waveforms at baseline
(B), 4.5 l/min (C), 6.0 l/min (D) and 7.5 l/min (E). With increased flow, there are greater
degrees of LV unloading and uncoupling between aortic and peak LV pressure
generation. CGS, cardiogenic shock.
(From Burkhoff D, Sayer G, Doshi D, et al. Hemodynamics of mechanical circulatory
support. J Am Coll Cardiol 2015;66-2671; with permission)
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Figure 2.9. Types of LVAD device

(A) Axial Flow Device
ventricle

(B) Centrifugal Device RA, right atrium; RV, right
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Figure 2.10. Total artificial heart

(A) Gore-tex (Gore Medical, Flagstaff, AZ) sheets are sewn into the pericardial well
with a few 4-0 prolene sutures. After coming off bypass, and hemostasis is achieved,
the sheets can be wrapped around the ventricles to prevent harm on reentry. (B)
Percutaneous lines exit 6-8 cm from left subcostal margin.
(From Morris RJ. The Syncardia total artificial heart; implantation technique. Oper
Tech Thorac Cardiovasc Surg 2012;17(@):164; with permission).
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Box 3:
Indications:
-

Patients who are heart transplant candidates with severe biventricular failure and
imminent risk of death (INTERMACS profiles 1 and 2) in setting where suitable
donor is not available.

-

Bridge to transplant in patients in need of re-transplantation experiencing graft
failure not responding to conventional therapy: Severe and diffuse coronary artery
vasculopathy.

-

Patient’s with infiltrative or hypertrophic cardiomyopathy and associated low
output failure versus cardiogenic shock. Knees are patients not amenable to left
ventricular systolic devices

-

Patient’s who experienced ventricular tachycardia storm or malignant arrhythmias
despite multiple ablations and medical therapy.

Contraindications:
-

Patients for ultimately not deemed to be transplant candidates

(Data From Arabia F. Total artificial heart. In: Kobashigawa JA, editor. Clinical guide to
heart transplantation. Cham, Switzerland: Springer; 2017. P. 227-236.)
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Chapter Three: Markers of Frailty in Patients Undergoing Left Ventricular Assist
Device Implantation
Abstract
Background: Frailty has been linked to adverse clinical outcomes, disability,
increased hospital length of stay (LOS), readmissions and increased mortality. Several
markers of frailty are associated with aging and other co-morbid conditions leading to
uncertainty about their applicability to patients undergoing evaluation for Left
Ventricular Assist Device (LVAD) implantation. The purpose of the study was to identify
a feasible frailty measure in adults with end-stage HF who underwent LVAD
implantation. In order to determine the best marker of frailty in LVAD patients, we tested
the hypothesis that frailty would predict 30 day rehospitalization rates using Fried’s
criteria, SPPB, handgrip strength, serum albumin and 6MWT in patients undergoing
LVAD implantation.
Methods: A total of 23 patients were recruited and enrolled between January
2015 and May 2016. This was an observational cohort study in which Fried’s criteria,
SPPB, handgrip strength, serum albumin levels, and 6MWT were measured prior to
LVAD implantation. Hospital readmissions was measured to examine the relationship
between measures of frailty and 30-day rehospitalization rates.
Results: A total of 23 patients met eligibility criteria and were included in the
analysis. Patients were labeled as frail or non-frail for each measurement of frailty. The
vast majority of patients were labeled as frail. All patients were frail as measured by selfreported exhaustion. Albumin, low physical activity and 6MWT were similar with
approximately 91% of patients being measured as frail. Fried’s criteria labeled 87% as
frail followed by gait speed (69.6%), Chair sit to stand (69.6%), Weight loss (65.2%),
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Short Performance Physical Battery (60.9%) and Balance (56.5%). Handgrip was least
likely to measure one as frail (52.2%). During the 30-day follow-up period, 7 patients
were readmitted to the hospital. Handgrip strength and 6MWT were the only two frailty
indicators differed between those who were readmitted and not readmitted within 30days. Handgrip strength was the only marker predictive of hospital readmission and it had
a negative association. Compared to those who were not frail, frail patients by handgrip
criteria were 93.4% less likely to be admitted (p = 0.033).
Conclusion: Changes associated with the disease process of patients with end
stage heart failure undergoing LVAD implantation makes it difficult to identify markers
of frailty in this population. The findings of our study indicate that none of the markers
are good predictors of frailty in patients with advanced heart failure with LVADs because
they all identify a vast majority of the patients as frail.
Introduction
Chronic heart failure is a devastating and progressive condition affecting over 5.7
million Americans, and demands enormous resources which together account for 2-3% of
the national health care budget.- The number of adults with heart failure is expected to
exceed 8 million and the annual costs is expected to increase from $30.7 billion to $69.7
billion by 2030. Readmission rates remain a burden with approximately 50% of all
patients being readmitted within six months and 25% being readmitted within 30 days.
As heart failure progresses and becomes advanced, morbidity and mortality increase even
further.
The high rate of morbidity and mortality combined with increased costs for
readmissions associated with advanced heart failure has led to the development of
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advanced treatments such as implantable left ventricular assist devices (LVADs). While
the use of LVADS is associated with a significant reduction in morbidity and mortality
among patients with advanced heart failure compared to medical treatment alone, the
costs associated with this technology remain high with an estimated cost per qualityadjusted years of over > $400,000. Moreover, despite advances in technology,
complications associated with LVADs such as infection, bleeding and stroke remain
high. Minimizing complications in this population is essential to reducing
rehospitalization rates and healthcare costs. It is important to identify those who are most
likely to benefit from an LVAD and also identify those who are most likely to have
complications associated with LVAD implantation. General guidelines and criteria for
patient eligibility have been established and include the following: 1) severe symptomatic
end-stage heart failure despite optimal medical therapy; 2) left ventricular ejection
fraction (LVEF) less than or equal to 25 percent; 3) exercise VO2 less than or equal to 12
ml/kg/min; and 4) continuous intravenous inotropes or intra-aortic balloon pump therapy
to prevent symptomatic hypotension, decreasing renal function or worsening pulmonary
congestion., Choosing patients for LVAD remains a challenge because these patients are
often deconditioned and unstable due to the progression of their disease with a high risk
of adverse events after cardiac surgery., Additionally, the overall physical condition of
the patient is an important consideration particularly with respect to the capacity of the
patient to participate in their own physical rehabilitation following LVAD implantation.
Consequently, the concept of frailty has emerged as an important factor for appropriate
patient selection.
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Frailty is defined as an increased vulnerability due to age or physical condition
because of decline in physiological reserves or function that compromises the ability of
the patient to adjust to acute stressors., In the Cardiovascular Health Study, frailty was
defined according to Fried’s Criteria: 1) poor grip strength; 2) slow gait; 3) low level of
physical activity; 4) low energy or self-reported exhaustion; and 5) unintentional weight
loss. Meeting a minimum of 3 criteria was defined as frail.
Frailty has been linked to adverse clinical outcomes, disability, increased hospital
length of stay (LOS), readmissions and increased mortality., , , Frailty has been studied in
the elderly population and in patients undergoing cardiac surgery but not well studied in
patients undergoing LVAD implantation. , , Fried’s criteria is the most commonly used
measurement of frailty in patients with LVADs. Several components of Fried’s frailty
score including decreased gait speed, self-reported exhaustion, low physical activity and
weight loss are associated with aging and other co-morbid conditions leading to
uncertainty about their applicability to patients undergoing evaluation for LVAD
implantation.
Another commonly used validated measure of frailty is the short physical
performance battery test (SPPB). The SPPB assesses gait speed, balance and lower
extremity muscle strength to identify those who are frail. The SPPB has been well studied
in other populations including those with heart failure and identifies patients who are at
high risk for progressive disability, increased hospital length of stay and mortality., The
SPPB has not been used in patients with end-stage heart failure undergoing evaluation for
LVAD implantation.
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While Fried’s criteria and the SPPB are common measures of frailty, they are
complicated to administer because they include multiple components with different
modes of assessment. Identifying a more suitable measure of frailty that is feasible and
sensitive in patients with LVADs is essential. Single markers of frailty may be a better
indicator of frailty in this population., , Clinical evidence from the heart failure literature
suggest that handgrip strength, albumin and six minute walk distance improve after
LVAD placement, therefore these markers may be good measurements of frailty for this
population.,
Handgrip strength is a simple and effective measure of frailty. Assessing handgrip
strength prior to LVAD implantation may aid in determining LVAD candidacy, as
reduced handgrip strength identifies those at risk for increased LOS following LVAD
implantation. Reduced handgrip strength is a predictor of reduced survival after VAD
implantation, in addition to post-operative outcomes including bleeding and infection.
Thus, handgrip strength may be a good individual marker for frailty in LVAD patients.
Serum albumin is an indicator of disease severity in patients with heart failure and
has been shown to be associated with increased mortality and morbidity., Up to 49% of
patients with heart failure have hypoalbuminemia and serum albumin is an inexpensive
marker recently proposed for the identification of patients with heart failure at risk of
adverse outcomes. In patients with LVADs, pre-implantation albumin was identified as a
indicator of 3 month mortality post LVAD implantation and is associated with prolonged
hospitalization in patients undergoing LVAD implantation., In addition, postimplantation normalization of albumin levels is associated with improved survival.
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Based in these findings, serum albumin may be a good single marker of frailty in LVAD
patients.
The Six Minute Walk Test (6MWT) is associated with frailty and predicts
mortality in older patients with heart failure. Furthermore, changes in 6MWT distance
predict rehospitalizations. In patients with LVADs, the 6MWT is associated with
functional decline and patients walking less than 300 meters have increased mortality.
The 6MWT is feasible for patients with acute heart failure and can be used to assess
baseline status and response to therapy, and thus might be a good single marker for frailty
in LVAD patients.
It is anticipated that identification of frailty in patients would enhance patient
selection for LVAD implantation and potentially identify patients whose frailty is likely
to reverse following successful implantation of LVAD. The purpose of the study was to
identify a feasible frailty measure in adults with end-stage HF who underwent LVAD
implantation. In order to determine the best marker of frailty in LVAD patients, we tested
the hypothesis that frailty would predict 30 day rehospitalization rates using Fried’s
criteria, SPPB, handgrip strength, serum albumin and 6MWT, in patients undergoing
LVAD implantation.
Methods
Study design
This was an observational cohort study conducted at a major academic medical
center in which Fried’s criteria, SPPB, handgrip strength, serum albumin levels, and
6MWT were measured prior to LVAD implantation. Hospital readmissions were
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measured to examine the relationship between measures of frailty and 30-day
rehospitalization rates.
Sample and setting
After receiving Institutional Review Board approval for the study, a total of 23
patients were recruited and enrolled between January 2015 and May 2016 from a hospital
associated with a major academic health center. Eligible participants were patients with a
diagnosis of end-stage heart failure with reduced ejection fraction < 25% who were
classified as New York Heart Association (NHYA) Class IV and who were scheduled to
undergo LVAD implantation. All eligible patients during the enrollment time period
agreed to participate and provided signed informed consent. Patients who could not
complete the physical tests (n = 1) or who died before discharge (n = 1) were not eligible
for the study.
Measurement of variables
These variables were measured in the patient’s room prior to LVAD implantation.
All data were collected within 1 week prior to implantation.
Fried’s Criteria
Fried’s Criteria includes the following domains: 1) self-reported exhaustion; 2)
physical activity; 3) weight loss; 4) strength; and 5) gait speed.
Self reported exhaustion was measured by asking the patient the following 2
questions from the Center for Epidemiologic Studies Depression Scale (CES-D): How
often in the past week did you feel like everything you did was an effort and how often in
the past week did you feel like you could not get up and going? Answers were
categorized into 2 groups: Often (> 3 days) or not often (0-2 days). Those who answered
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often were labeled as frail. The CES-D scale is the most common instrument used in the
Fried’s criteria to examine self-reported exhaustion.
Low physical activity was measured by asking the patient a single question to
identify self-reported physical activity: Over the past week (even if it was not a typical
week), how much time did you exercise or were you physically active (included both
exercise and your usual activities of daily living)? The answers were categorized into (1)
None; (2) Less than 30 minutes/week; (3) 30-60 minutes/week; (4) More than 60
minutes/week. More than 60 minutes a week was defined as being physically active, less
than 60 minutes was defined as having low physical activity. The single-item question
that was used was easy to complete and construct and validity have previously been
established and have been used in several previous populations including patients with
heart failure.
Weight loss was self-reported by asking the patient if they had ≥ 10 pound weight
loss in the prior year. This is the most commonly utilized way of measuring weight loss
for Fried’s criteria. ,
Strength was measured using handgrip strength, which is associated with
increased mortality, bleeding and infection after LVAD implantation. It was measured in
the dominant hand using a Jamar Hydraulic Hand Dynamometer (JLW Instruments,
Chicago, IL), which is an accessible, widely used device. Handgrip strength was
measured by a nurse practitioner who was trained by an exercise physiologist. Patients
were asked to perform a maximal isometric contraction for 5 seconds with their dominant
hand three times with a 30 second rest period between each contraction. Strength was
defined as the average of the 3 contractions. Patients whose handgrip was less than 25 %
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of their body weight in kilograms were labeled as frail. Those with a handgrip strength
greater than 25% of their body weight in kilograms were labeled as non-frail.
Gait speed was measured as follows by the nurse practitioner. A cone was placed
at the starting point and at the end point with a distance of 4 meters measured by a tape
measure in between the starting and end point. Gait speed was measured with a stop
watch and was defined as the time required for the participant to walk from the beginning
to the end. Gait speed is identified as a predictor of mortality and morbidity in patients
undergoing cardiac surgery and has been identified as a frailty indicator in patients with
advanced heart failure.,
Short performance battery test
The short physical performance battery test (SPPB) was used to measure lower
extremity functional ability. The SPPB was conducted by a physical therapist. The SPPB
is used to evaluate frailty using a series of three physical performance tests (gait speed,
chair rises and tandem balance). Gait speed was measured as described above. Chair
raises were conducted in the participant’s room. The participant was asked to go from
sitting to standing position with arms were folded across chest 5 times as quickly as
possible without stopping and was timed. Tandem balance was measured with feet
positioned in 3 different positions (feet together, semi tandem with the heel of one foot
placed by the big toe of the other foot and full tandem with feet directly in front of each
other). The participant was asked to stand in each position for 10 seconds and was
allowed to use arms, bend knees or move their body to maintain balance. Each tandem
position was scored with a range of 0 to 4 (0= couldn’t perform, 1 = needed assistance to
perform, 2 = performed with great difficulty by themselves, 3 = performed with some
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discomfort, 4 = performed without difficulty or discomfort). After each tandem position
was scored, the three measures were added together for a total score that ranged from 0
(worst performance) to 12 (best performance). Patients were classified as frail (SPPB
score < 6), borderline frail (SPPB score 7-9) or non-frail (SPPB score ≥ 10). The SPPB
has been shown to have predictive validity for mortality, increased hospitalization and
disability in older adults.,
Serum Albumin
Hypoalbuminemia is a prognostic indicator in patients with heart failure and is
associated with increased mortality and unfavorable outcomes., Serum albumin levels
(g/dl) were measured by standard laboratory techniques. Serum albumin levels were
collected at the time of the patients pre-operative routine laboratory work on the day of
surgery and analyzed in the clinical laboratory at the hospital. Patient were categorized
according to serum albumin level (frail < 3.5 g/dl and as non-frail > 3.5 g/dl).
Six minute walk test
The 6MWT has been identified as an important outcome measure of functional
capacity in people with severe heart failure and is a marker of frailty. The 6MWT is safe,
easy to administer and has been found to be reliable predictor of post-LVAD mortality. A
nurse practitioner or physical therapist instructed the patients to walk for 6 minutes down
a hallway free of obstacles at a pace at which they felt comfortable. Patients were
permitted to use a walker or cane if needed and rest breaks were permitted, although time
recording does not stop with any break. The hospital hallway was marked in 1 meter
increments and the total distance in meters walked in 6 minutes was recorded. Patients
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walking less than 300 meters were classified as frail. Those walking greater than 300
meters were classified as non-frail.
Sociodemographic and Clinical Variables
Gender, age, marital status, body mass index, comorbidities, and heart failure
etiology (ischemic vs non-ischemic) were obtained from the medical record. Comorbidity
data included diabetes, coronary artery disease and chronic kidney disease.
Hospital Readmission
Hospital readmission data was obtained from the medical record. Time to hospital
readmission was defined as time from date of discharge to the date of rehospitalization
for any cause.
Data analysis
Demographic and clinical characteristics were reported using frequencies and
percentages for categorical variables and mean ± standard deviation for continuous
variables. Frequencies were used to determine frailty for each measure. Chi-square
analysis was used to determine if the measures of frailty were predictive of 30 day. All
analysis was conducted using SPSS software.
Results
A total of 23 patients met eligibility criteria and were included in the analysis.
Patient characteristics are presented in Table 3.1. The average age of patients was 59 ± 9
years. Almost all participants were male and married. The primary etiology of heart
failure for this population was ischemic cardiomyopathy. Over two-thirds of the patients
had coronary artery disease and over half of the patients had diabetes mellitus. Chronic
kidney disease was prevalent in nearly half of the patients.
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Patients were labeled as frail or non-frail for each measurement of frailty which is
presented in Table 3.2. All patients were frail as measured by self-reported exhaustion.
Albumin, low physical activity and 6MWT were similar with approximately 91% of
patients being measured as frail. Handgrip was least likely to measure one as frail.
During the 30-day follow-up period, 7 patients were readmitted to the hospital.
Median hospital length of stay was 19 days and median length of stay in the intensive
care unit was 8 days. The most common cause for readmission was acute heart failure
symptoms (n = 6). Only two frailty indicators differed between those who were
readmitted and not readmitted within 30-days. These were handgrip strength and 6MWT.
Of those admitted within 30 days of discharge, 14.3% were frail by handgrip criteria,
while of those not admitted, 68.8% were frail by handgrip criteria. Of those admitted
within 30 days of discharge, 71.4% were frail by 6MWT criteria, while of those not
admitted, 100% were frail by 6MWT criteria. (Table 3.3). With the exception of
handgrip strength, none of the criteria were predictive of hospital readmission (Table
3.4). Compared to those who were not frail, frail patients by handgrip criteria were 93.4%
less likely to be admitted (p = 0.033).
Discussion
The study demonstrated several indicators of frailty in patients with advanced
heart failure undergoing LVAD implantation and which measurements were predictive of
30 day re-hospitalization. The findings of our study indicate that measures of frailty that
contain multiple components such as Fried’s criteria and SPPB, and measures that are
single markers such as handgrip, 6MWT and albumin are not good predictors of frailty in
patients with advanced heart failure with LVADs.
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We found that nearly 87% of patients with advanced heart failure undergoing
LVAD implantation were frail according to Fried’s criteria and 85% of those patients
were readmitted within 30 days. While the Fried’s criteria is the most commonly used
measurement of frailty in patients with HF and those with LVAD’s, it has been suggested
that Fried’s criteria may not be applicable in patients with advanced heart failure
undergoing LVAD implantation. The Fried criteria was originally developed to define
frailty in a population of ambulatory adults. Due to the progression of disease and
inflammatory response leading to deconditioning and debilitation, these measurements
may not accurately reflect frailty in patients with advanced heart failure undergoing
LVAD implantation.
Some criteria such as self-reported exhaustion, self-reported physical activity, and
weight loss may not be accurate in this population. Weight loss may be masked by
volume overload in the setting of end-stage HF leading to inaccurate assessment of
weight loss in the past year. Most patients with end-stage heart failure are not able to
perform activity of daily living and have limited ambulation due to symptoms associated
with heart failure including fatigue, shortness of breath and weakness. Therefore, selfreported exhaustion and self-reported physical activity may not accurately reflect frailty,
but may be only associated with disease progression of heart failure.
The SPPB has been identified as a frailty indicator in patients with advanced heart
failure and are predictive of outcomes. However, this was not found in our study. The
SPPB is sensitive to the physiological decline associated with aging and is influenced by
cognition and motivation which play a role in determining prognosis in frail patients with
HF. The SPPB integrates the effects of physiological decline, malnutrition and
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comorbidities. However, the SPPB is influence by severity of illness and symptoms and
may not be feasible for many hospitalized patients. By comparing individual components
of this integration will allow for the possibility of markers of frailty that are easier to
administer.
One component of the SPBB and Fried’s criteria is gait speed. Our study did not
support the findings of other investigators., Gait speed in patients with advanced heart
failure undergoing LVAD implantation was not predictive of readmission and identified
frailty in about two-thirds of the patients. Gait speed has been identified as a single
measure of frailty and was found to be predictive of 6 month mortality when compared to
Fried’s criteria in other populations., It is a preferred measure of frailty compared to
SPPB and Fried’s criteria because it is quick to administer and practical and provides
useful prognostic information., However, its applicability to patients undergoing LVAD
implantation may be limited. There is a significant minority of patients who are not
ambulatory or are unable to perform the activity. Alternative measures such as handgrip
strength may be more feasible in this population.
Handgrip was not a good measurement of frailty based on our findings. It
identified few patients as frail. This contradicts other studies that support handgrip
strength as a good predictor of frailty., To my knowledge no studies have examined
length of stay to handgrip strength or prediction of handgrip strength to 30 day
readmission. Our study found that handgrip strength was the only measure that predicted
30 day readmission but the relationship was a negative association. For those who were
frail by handgrip strength, they were more likely to not be admitted. The wide confidence
interval indicates that this is not a precise measurement which may due to the small
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sample size. Handgrip has been linked to increased length of stay when examined as part
of Fried’s criteria in relation to outcomes and hospitalization.
Measures such as gait speed, and 6MWT mainly use lower extremity strength to assess
functional ability, handgrip strength is performed with minimal exertion using upper
body strength, which could account for the difference of frailty classification.
Post-LVAD implantation 6MWT has been examined and is associated with
increased mortality. It has been validated to measure functional capacity and outcomes in
heart failure, but its utility in patients with LVADs in the context of frailty is unknown.
The 6MWT identified over 90% of our patients as frail and is not a good measure of
frailty in patients with advanced HF undergoing LVAD implantation. This is the only
study to examine the 6MWT as an indicator of frailty in comparison to multiple other
measures and to assess if 6MWT predicts re-hospitalization.
Albumin identified over 91% of our patients as frail, yet it was not predictive of
30 day readmission. It is not a good indicator of frailty in patients with advanced HF
undergoing LVAD implantation. It is well understood that patients with heart failure
often have cardiac cachexia so the likelihood of unintentional weight loss is prevalent in
most of the population reaching end stage heart failure. As a result, malnutrition is
inevitable and is associated with postoperative complications, prolonged hospitalizations
and poor outcomes. Furthermore, hypoalbuminemia, as a marker of malnutrition, is
associated with morbidity and mortality and low albumin levels (<2.5 mg/dl) are
associated with mortality and morbidity after LVAD implant. In addition, pro-longed
post-operative length of stay is also associated with low albumin levels.
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To my knowledge this is the first study to compare these measures of frailty in
patients with LVADs. Identification of patients at high risk for functional decline and
poor outcomes is crucial when considering LVAD and patient selection is important to
attain a favorable outcome. One of the most difficult challenges is differentiating between
underlying conditions such as inflammatory, malnutrition, low activity levels that can
occur with both frailty and heart failure.
There are some limitations that should be acknowledged in the interpretation of
the present data. This was a single-center study and the results may not be generalizable
to other patients at other centers. The number of patients in the study was small and we
were limited in the number of factors we could adjust for in the analysis. Heterogeneity
among groups of patients should be considered in future research and indicate which
fraction of patients are bridge to transplant versus destination therapy. Patients considered
for destination LVAD tend to be older and have more comorbid illnesses. Future research
should also focus on broader range of outcomes and include a larger sample size. In
addition, future research should focus on additional predictors of frailty and interventions
or changes in management that will improve frailty prior to LVAD implantation.
Conclusion
Changes associated with the disease process of patients with end stage heart
failure undergoing LVAD implantation makes it difficult to identify markers of frailty in
this population. The findings of our study indicate that none of the markers are good
predictors of frailty in patients with advanced heart failure with LVADs because they all
identify a vast majority of the patients as frail. Given these findings, it may be more
beneficial to focus on which measures of frailty improve post-implantation.
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Table 3.1: Patient demographic and clinical characteristics N = 23
Characteristics
Sociodemographics
Age, years
Gender
Male
Female
Marital stats
Married or cohabiting
Living with other family
Readmitted within 30 days
No Readmitted
Readmitted
Clinical Characteristics
Body mass index, m2/kg
6 minute walk, meters
Albumin, mg/dl
Etiology of Heart Failure
Non-ischemic cardiomyopathy
Ischemic cardiomyopathy
Coronary artery disease (CAD)
Do not have CAD
Have CAD
Diabetes mellitus (DM)
Do not have DM
Have DM
Chronic kidney disease (CKD)
Do not have CKD
Have CKD

Mean ± SD or N (%)
59.61 ± 9.58
21 (91.3)
2 (8.7)
22 (95.7)
1 (4.3)
16 (69.6)
7 (30.4)
29.22 ± 5.70
189.04 ± 84.163
2.75 ± 0.43
8 (34.8)
15 (65.2)
7 (30.4)
16 (69.6)
10 (43.5)
13 (56.5)
12 (52.2)
11 (47.8)
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Table 3.2: Comparison of Left Ventricular Assist Device Patient Characteristics Between
Patients Readmitted Within 30 Days and Those not Readmitted, N = 23
Characteristics

Sociodemographics
Age, years
Gender
Male
Female
Marital stats
Married or cohabiting
Living with other family
Clinical Characteristics
Body mass index, m2/kg
Albumin, mg/dl
6 minute walk, meters
Non-ischemic
cardiomyopathy
Coronary artery disease
Diabetes mellitus
Chronic kidney disease
Frailty Characteristics
Fried Criteria, yes frail
Short Performance Physical
Battery, yes frail
Hand grip, yes frail
Albumin, yes frail
6 minute walk test, yes frail
Low physical activity, yes
frail
Gait speed, yes frail
Weight loss, yes frail
Balance, yes frail
Chair sit to stand, yes frail
Self-reported exhaustion,
yes frail

Not Readmitted, n =
16
Mean ± SD or N
(%)

Readmitted, n =
7
Mean ± SD or N
(%)

P

59.7 ± 10.8

59.4 ±6.7

0.95

15 (93.8)
1 (6.3)

6 (85.7)
1 (14.3)

0.56

15 (93.8)
1 (6.3)

7 (100)
0

0.39

30.2 ± 4.7
2.75 ±.50
177.1 ± 74.6
7 (47.8)

26.9 ± 7.5
2.76 ± .21
216.3 ± 104
1 (14.3)

0.20
0.97
0.31
0.15

10 (62.5)
8 (50.0)
11 (68.8)

6 (85.7)
5 (71.4)
0 (0)

0.24
0.33
0.001

14 (87.5)
11 (68.8)

6 (85.7)
3 (42.9)

0.91
0.25

11 (68.8)
14 (87.5)
16 (100.0)
15 (93.8)

1 (14.3)
7 (100)
5 (71.4)
6 (85.7)

0.01
0.22
0.02
0.55

12 (75.0)
10 (62.5)
10 (62.5)
11 (68.8)
16 (100)

4 (57.1)
5 (71.4)
3 (42.9)
5 (71.4)
7 (100)

0.40
0.68
0.38
0.90
n/a
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Table 3.3: Categorization of Left Ventricular Assist Device Patients as Not Frail or Frail
for Each Individual Frailty Measure, N = 23
Measure

Not frail

Frail

N (%)

N (%)

Fried Criteria

3 (13)

20 (87)

Short Performance Physical Battery

9 (39.1)

14 (60.9)

Hand grip

11 (47.8)

12 (52.2)

Albumin

2 (8.7)

21 (91.3)

6 minute walk test

2 (8.7)

21 (91.3)

Low physical activity

2 (8.7)

21 (91.3)

Gait speed

7 (30.4)

16 (69.6)

Self-Reported exhaustion

0

23 (100)

Weight loss

8 (34.8)

15 (65.2)

Balance

10 (43.5)

13 (56.5)

Chair sit to stand

7 (30.4)

16 (69.6)
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Table 3.4: Frailty Predictors of 30 day Readmission
B

Odds Ratio

95%

P

Confidence
Interval
Fried’s Criteria

-.154

.857

.065-11.357

.91

SPPB

-1.076

.341

.055-2.131

.250

Handgrip

-2.580

.076

.007-.807

.033

Albumin

.040

1.041

.126-8.598

.970

6MWT

0.006

1.006

.995-1.017

.304

Legend: Short Physical Performance Battery (SPPB), Six Minute Walk Test (6MWT)
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Chapter Four: Factors of Frailty That Improve Post VAD
Abstract
Background: Frailty has been identified as a prognostic marker for adverse
outcomes in patient with heart failure and patients undergoing cardiac intervention and
surgery. There is minimal information regarding outcomes and short-term improvement
in frailty post Left Ventricular Assist Device (LVAD) implantation. Three objective
measures that reflect frailty and that have been used by others to measures frailty in
patients with heart failure but not in LVAD patients or to predict outcomes include
handgrip strength, the six minute walk test (6MWT) and serum albumin. Thus, we chose
these three measures to reflect frailty and the purpose of the study was to determine
whether frailty measures improve 3 months post LVAD implantation and to compare
sensitivity of these three measures to change in frailty.
Methods: This was a 3 month longitudinal cohort study of 23 patients with
advanced heart failure who underwent LVAD implantation. Patients were enrolled
between January 2015 to May 2016 and within 1 week of scheduled date of LVAD
implantation. Patients of all ages and implantation strategy were included. Frailty was
reflected by handgrip strength, 6MWT and serum albumin.
Results: Prior to LVAD implantation, frailty measurements by handgrip strength
identified 12 patients as frail compared to 22 patients by 6MWT and 21 patients by
albumin. Post LVAD measurements of frailty identified 13 as frail by handgrip, 11 by
6MWT and 9 by albumin. There was no difference in handgrip strength from preimplantation and post-implantation. Only 8% of patient walked 300 meters or more in 6
minutes prior to LVAD implantation. In contrast, 53% of patients were able to walk more
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than 300 meters at 3 months post-implantation with an average 47% improvement in
6MWT distance (p = 0.002). Mean distance walked increased significantly from pre- to
post-implantation (p < 0.001). Pre-operatively 21 (91.3%) patients met criteria for frailty
based on serum albumin cut-point and post-operatively 9 (39.1%) met frailty criteria (p =
0.002). Mean serum albumin increased significantly pre- to post-implantation (p <
0.001).
Conclusion: In patients with heart failure who undergo LVAD implantation, the
6MWT and serum albumin measurements are reflect short-term improvement in frailty
and these simple measures may be used to determine those patients who are responsive to
LVAD implantation. Frailty by select markers is likely to improve in most people after
LVAD implantation, and thus frailty should not preclude candidate selection for an
LVAD.
Introduction
Heart failure is a progressive condition that affects 5.7 million Americans with
more than 670,000 new cases each year. Approximately 100,000 patients with heart
failure in the United States are unresponsive to maximal medical therapy resulting in
further deterioration, rehospitalization, and death. The high rate of morbidity and
mortality, and poor quality of life associated with heart failure has led to exploration of
additional treatments for those with advanced heart failure that include left ventricular
assist devices (LVADs).
Despite improvement in morbidity and mortality with LVADs, multiple
complications such as stroke, bleeding and device-related infections occur. The cost
associated with these treatments is extensive. , , , Consequently, it is crucial to identify
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patients who are most likely to benefit from a LVAD. One potential factor that may be
important to patient selection is frailty.
Frailty has been identified as a prognostic marker for adverse outcomes including
death, disability and rehospitalization in patient with heart failure and patients undergoing
cardiac intervention and surgery., , , , , Frailty reflects physiological changes across many
organ systems due to a decrease in physiological reserve and to vulnerability caused by
physical and psychological stressors such as acute or chronic illness. When exposed to
stressors, patients who are frail are at risk for further decompensation, adverse events,
complications, longer recovery, functional decline and mortality. , , ,
Frailty in the elderly community and in patients undergoing cardiac surgery leads
to adverse outcomes and increased mortality and morbidity.,, , , Recently, there has been a
growing interest in the effect of frailty on patients undergoing LVAD. Frailty is prevalent
in 21% of patients with advanced heart failure who undergo LVAD implantation and is
associated with increased hospital length of stay, higher risk of hospital readmission and
increased hospital length of stay.
Little is known about frailty in patients with an LVAD and most of the research
has focused on how frailty may impact prognosis and outcomes after LVAD
implantation. There is minimal information regarding short-term improvement in frailty
post LVAD implantation. Clarification of how frailty improves post LVAD will allow for
better patient selection to ensure that those undergoing LVAD implantation benefit from
the device with minimum complications and are most likely to recover. It typically takes
approximately 3 months for patients to recover from post-surgical changes, undergo
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rehabilitation, and adapt to their new lifestyle. Further information is warranted to
determine if short-term measures in frailty improve during this time frame also.
To date, there is no gold standard definition of frailty. In order to attempt to
operationalize the definition of frailty, Fried proposed a clinical phenotype which defines
frailty as meeting three out of five phenotypic criteria: 1) slowness; 2) unintended weight
loss; 3) inactivity; 4) exhaustion; and 5) decreased grip strength.,, The subjectivity of
some of these indicators and their universality among individuals with advanced heart
failure suggest that use of Fried’s criteria may be inappropriate with patients with endstage heart failure. Three objective measures that reflect frailty and that have been used
by others to measures frailty in patients with heart failure but not in LVAD patients or to
predict outcomes include handgrip strength, the six minute walk test (6MWT) and serum
albumin. Thus, we chose these three measures to reflect frailty and the purpose of the
study was to determine whether frailty measures improve 3 months post LVAD
implantation and to compare sensitivity of these three measures to change in frailty.
Methods
This was a 3 month longitudinal (from one week pre-implant to 3 months post
LVAD implant) cohort study of 25 patients with advanced heart failure who underwent
LVAD implantation.
Subjects
Patients were enrolled between January 2015 to May 2016 at a major medical
center and within 1 week of scheduled date of LVAD implantation. Patients of all ages
and implantation strategy (i.e., bridge to transplant or destination therapy) were eligible
for the study if they (1) had a physician diagnosis of advanced heart failure as

82

documented in the hospital medical records with a confirmed left ventricular ejection
fraction (LVEF) < 25% by echocardiography and (2) were able to complete required
physical tests (i.e., handgrip strength and 6MWT). A total of 25 eligible patients agreed
to participate in the study during the enrollment period. One patient was physically
unable to perform the 6MWT at 3 months post-implantation and one patient died prior to
3 month follow-up resulting in a final sample of 23 patients.
Measures
Frailty was reflected by handgrip strength, 6MWT and serum albumin.
Handgrip strength. Handgrip strength was measured in the dominant hand using
a hydraulic hand dynamometer by Jamar Hydraulic Hand Dynamometer (JLW
Instruments, Chicago, IL). The patient was permitted to stand or sit with arms at their
side not touching their body and elbow bent slightly. They were instructed to squeeze the
dynamometer with as much force as possible for five seconds. Handgrip strength was
recorded as the average force to the nearest kilograms of 3 trials spaced 30 seconds apart
to avoid muscle fatigue. Patients whose handgrip force was < 25% of their body weight
in kilograms were categorized as frail. The pre-LVAD handgrip strength was measured
by a nurse practitioner in the patient’s hospital room within 1 day of LVAD implantation.
Post- LVAD handgrip strength was measured in the clinic room at each patients’ 3 month
routine follow-up visit by the same nurse practitioner.
Six minute walk test. Patients were instructed to walk down a hallway free of
obstacles at a comfortable pace for 6 minutes. They were permitted to use a walker or
cane if needed and take rest break although timing continued. To improve accuracy of
measured distance, 100 meters of the hallway was marked in 1 meter intervals. A stop
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watch was used to time the test. The total distance walked after 6 minutes was
documented. Patients walking < 300 meters were categorized as frail. The 6MWT was
conducted by a nurse practitioner or physical therapist. The pre-LVAD implantation
6MWT was conducted in a hospital hallway. The post LVAD implantation 6MWT was
conducted in the clinic hallway at the 3 month routine follow-up visit.
Albumin. Blood for serum albumin levels was collected as part of the patients’
routine pre-operative laboratory work and as part of their routine 3 month postimplantation laboratory work. Serum was analyzed in the clinical laboratory. Patients
were classified as frail if they had an albumin level < 3.5 g/dl.
Procedure
Approval to conduct the study was received from the Institutional Review Board.
Patients admitted for LVAD implantation were recruited for the study by the advanced
heart failure team. The nurse practitioner for the team explained the study to patients and
asked them to participate in the study. If they agreed, the nurse practitioner obtained
written consent while the patient was in the hospital prior to LVAD implantation.
Demographic and clinical data were retrieved from hospital medical records at baseline
and 3 months post LVAD implantation. These data were age, gender, albumin, body
mass index (BMI in kg/m2), etiology of cardiomyopathy (ischemic vs non-ischemic),
living arrangements and comorbidities (i.e., coronary artery disease [CAD], diabetes
mellitus [DM] and chronic kidney disease [CKD]). Heart failure related data included
diagnosis documented by physician from echocardiogram with LVEF < 25%. The
6MWT and handgrip were measured at baseline and at 3 months post LVAD
implantation per study protocol.
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Data Analysis
Demographic and clinical characteristics were reported using frequencies and
percentages for categorical variables and mean ± standard deviation for continuous
variables. Frequencies were used to determine frailty for each measure. Paired t-tests
were used to determine differences between pre- and post- 6MWT, handgrip strength,
and serum albumin levels. McNemar’s chi-square tests were used to compare proportions
of individuals within each frailty category from pre- to post-implantation.
Results
Patient characteristics. The majority of patients were male (88%), over 40% were
under the age of 60 years, and 96% were married or cohabitating (Table 4.1). The body
mass index range was 16 kg/m to 44 kg/m pre-implant compared to 20 kg/m -39 kg/m
post-implant. Only one patient was underweight with a BMI less than 20 kg/m prior to
LVAD implant. Over 60% of patients had a BMI > 30 kg/m pre-operatively. Postoperatively 58% had a BMI > 30 kg/m and no patients had a BMI < 20 kg/m. The
primary etiology of heart failure for this population was ischemic cardiomyopathy (60%).
The most common comorbidity was CKD (52%), followed by DM (40%) and CAD
(36%).
Frailty measures. Frequencies of each frailty measure are listed in Table 4.2. Prior
to LVAD implantation, frailty measurements by handgrip strength identified 12 patients
as frail compared to 22 patients by 6MWT and 21 patients by albumin. Post LVAD
measurements of frailty identified 13 as frail by handgrip, 11 by 6MWT and 9 by
albumin. Comparison of pre-implantation and 3 month post-implantation frailty measures
are listed in Table 4.2. There was no difference in handgrip strength from pre-
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implantation and post-implantation. Only 8% of patient walked 300 meters or more in 6
minutes prior to LVAD implantation. In contrast, 53% of patients were able to walk more
than 300 meters at 3 months post-implantation with an average 47% improvement in
6MWT distance (p = 0.002). Mean distance walked increased significantly from pre- to
post-implantation (p < 0.001). Pre-operatively 21 (91.3%) patients met criteria for frailty
based on serum albumin cut-point and post-operatively 9 (39.1%) met frailty criteria (p =
0.002). Mean serum albumin increased significantly pre- to post-implantation (p <
0.001).
Discussion
Using three single objective markers for frailty, we identified two markers
sensitive to improvement after LVAD implantation. Both serum albumin and 6MWT
improved significantly from pre-implantation to 3 months after LVAD implantation.
There was no change in handgrip strength at 3 months after LVAD implantation. Alone
or together these two markers could be used to determine improvement in frailty after
LVAD implantation. These objective markers have advantages over self-reported
markers, such as exhaustion and physical activity, that are commonly used to reflect
frailty and that are subject to patient bias in reporting. Other, longer measures such as
Fried’s criteria are longer and can over-identify frailty.
Although there is no gold standard to measure frailty in patients undergoing VAD
implantation, it is important to assess for frailty in the patient selection process and assess
for improvement in frailty post implant because of increased risk of post-operative
complications, and increased morbidity and mortality with frailty. Our findings on frailty
measures that improve post-LVAD implantation are consistent with those of prior studies
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in which an improvement in 6MWT was found. Albumin levels have not been used as
markers of frailty, but has been found to predict outcomes. Our findings suggest serum
albumin may also be useful as a marker of frailty.
Hypoalbuminemia is a prognostic indicator in patients with heart failure and is
associated with poor prognosis after LVAD surgery. , , Low albumin levels are reported
to be present in patients with heart failure but are most prevalent in patients with end
stage heart failure who are undergoing LVAD implantation. 2, , , , , Our study findings
were similar to previous studies concluding 91% of patients having low albumin levels
prior to LVAD implantation and significant improvement in serum albumin levels post
LVAD implantation. This is consistent with previous findings that report improvement in
serum albumin levels post-LVAD implantation. Guvenc, et al (2107) supported that low
albumin levels are corrected within six months after LVAD implantation and Go et al
(2015) reported improvement in serum albumin in 94% of patients post LVAD at 1 year.
Patients in our study had improvement in serum albumin levels 3 months after LVAD
implantation suggesting that frailty as measured by serum albumin normalized in a
majority of patients.
We used the 6MWT based on findings from others studies of 6MWT and frailty.
Boxer et al. (2010) noted a high correlation between the 6MWT and frailty (as defined by
Fried Criteria) in patients with heart failure. In a recent study, Hasin et al. (2017) reported
that the 6MWT was the strongest predictor of post LVAD survival. Hasin et al. (2012)
assessed frailty by 6MWT, and their study did show an improvement in 6MWT after
LVAD implantation at 3 months but approximately 20-30% of patients in their study
failed to improve. In addition, they measured frailty at 3 months and 1 year and noted that
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after 3 months patients remained stable with very little improvement at 1 year. Our study
is consistent with these findings and we found that the 6MWT improved in 50% of
patient by 3 months.
In our study, handgrip strength did not change from baseline to 3 months post
LVAD implantation. Chung et al. (2014) studied monthly handgrip strength from
baseline to 36 months after LVAD implantation. They saw improvement at 3 months that
was sustained at 6 month where it plateaued. Our failure to show an improvement at 3
months may have been a result of our smaller sample size or the fact that 3 months seems
to be the point at which handgrip strength begins markedly improving. These findings
suggest that handgrip strength measured at 3 months may not be a good short-term
marker,
This study has several limitations. It was a single-center study with a small study
cohort. Because the cohort studied was homogenous, this limits generalizability to a
larger, more diverse population of patients undergoing LVAD implantation. The short
term nature of the study does not allow any conclusions regarding long-term
improvement in frailty.
Conclusion
In patients with heart failure who undergo LVAD implantation, the 6MWT and
serum albumin measurements reflect short-term improvement in frailty and these simple
measures may be used to determine those patients who are responsive to LVAD
implantation. Frailty by select markers is likely to improve in most people after LVAD
implantation, and thus frailty should not preclude candidate selection for an LVAD.
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Table 4.1: Patient Demographic and Clinic Characteristics, n = 23
Characteristic

N (%) or mean ± SD

Age, years
Sex
Male
Female
Marital status
Married
Not Married
Body Mass Index, m2/kg
Pre-Implantation
Post-Implantation
Etiology
Ischemic
Non-ischemic
Comorbidities
Coronary Artery Disease
Diabetes
Chronic kidney Disease
LVAD for destination
therapy

59 ±9.4
21 (91.3)
2 (8.7)
22 (91.3)
1 (4.3)
29.2±5.7
29.9 ±4.9
15 (65.2)
8 (34.8)
16 (69.6)
13 (56.5)
11 (47.8)
15 (65.2%)

Table 4.2: Comparison of Pre-Implantation and Post-Implantation Frailty Measures
Frailty Measure

Pre-operative
mean ± SD

Post-operative
mean ± SD

p-value

Handgrip Strength (kg)
Frail, n (%)
Six Minute Walk
(meters)
Frail, n (%)
Albumin (g/dl)
Frail, n (%)

22.8 ± 10.7
12 (52.2%)
186 ±83.2

24.7 ± 11.1
13 (56.5)
275 ± 121.1

0.060
1.00
<0.001

22 (95.7%)
2.7 ± .4
21 (91.3%)

11 (47.8%)
3.5 ±.4
9 (39.1%)

0.002
<0.001
0.002
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Chapter Five: Summary and Integration
The overall purpose of this dissertation was to determine which measures of
frailty were most likely to predict frailty in patients with end stage heart failure who were
undergoing LVAD implantation and to determine if measures of frailty improved post
LVAD implantation. The studies were conducted for the following aims: 1) determine
which measures of frailty measure frailty in patients with LVAD 2) determine if
measures of frailty improved post LVAD implantation 3) determine which measures of
frailty are predictive of 30 day readmission.
Frailty is an emerging concept that has gained interest over the last 30 years.
Initially, clinicians and researchers started examining frailty in older adults and for the
past decade, frailty has been an upcoming topic across many spectrums of disease,
especially in the field of cardiovascular medicine. Due to conflicting ideas about the
definition of frailty, researchers started focusing on recognition and relationship of
attributes between aging, disability and chronic disease in hopes of conceptualizing
frailty.
After a joint effort between multiple investigators, a general agreement described
the core definition of frailty as an “increase vulnerability to stressors due to impairments
in multiple, inter-related systems that lead to a decline in homeostatic reserve and
resilience.” This definition served as a foundation to explore distinct concepts and ways
to measure and distinguish frailty from deterioration due to chronic disease. Although an
agreement on the main core of frailty was established, a comprehensive definition was
lacking. Unique characteristics of frailty that spread across a continuum of frailty
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remained in question, especially when establishing criteria and the most commonly used
measures to label one as frail.
In an attempt to conceptualize frailty, Fried established 5 criteria to measure
frailty. The Cardiovascular Health Study validated the construct validity of these five
measures which include weight loss, weakness, exhaustion, slowness, and low activity.
Fried’s criteria is the most commonly used measure of frailty for most populations in
current research. However, most research validating Fried’s criteria has been conducted
in older, aging adults and not in populations with chronic disease so the validity in these
populations remains uncertain. Due to the severity of illness, overlap of physiological
responses and decrease in physical function associated with chronic disease, the question
of applicability of Fried’s criteria to patients with chronic heart failure remains.
Subsequently, this leads to the exploration of other measures that may be more
appropriate and easier to administer or measure in this population.
Patients with end stage heart failure suffer from physical deterioration,
malnutrition and chronic inflammatory response which all overlap with components of
frailty. Research has demonstrated that patients with HF who are frail are more likely to
die or have adverse outcomes compared to those without frailty. Given the mortality rates
of those with end stage heart failure, advanced therapies including surgical options are on
the rise for treatment.
Chapter two discusses the epidemiology and pathophysiology of heart failure and
surgical approaches for those with end stage heart failure. As discussed, heart failure
continues to increase in both incidence and prevelance and 5 year mortality is 80%.
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Heart failure is most common cause of re-hospitalization and is related to symptoms
caused by congestive exacerbations. Guideline directed therapy is essential to treating
heart failure but for those who are refractory to medication therapy surgical approaches
including heart transplant or LVADs are available to those who are candidates.
Heart transplant remains the gold standard with a 1 year survival rate of 90%.
Approximately 3500 heart transplants are performed annually in the United States. The
most common cause of post-transplant complications is early graft failure which can lead
to death. With advancements in immunosuppression, acute rejection rates trend
downward. Long term complications are mostly related to cardiac allograft vasculopathy
in addition to malignancy.
Despite promising results with heart transplantation, challenges remain due to a
shortage of donor organs in comparison to those listed. The use of mechanical circulatory
support, including LVADs, emerged and is used to offer patients an option for destination
therapy or bridge to transplant pending candidacy. Initially, pulsatile pumps were used as
a bridge to transplant and noted a 48% reduction in mortality compared with optimal
medical therapy. Durability of pulsatile pumps was an issue and continuous flow pumps
evolved. A recent analysis of the INTERMACS registry revealed an 89% 1 year survival
rate with the use of continuous flow pumps.
Due to the increasing number of patients with advanced heart failure, the current
strategy for screening patients for heart transplantation and LVAD is gaining acceptance.
Regardless of which surgical option is decided upon, the benefits of transplant and
ventricular assist devices outweighs pharmacological treatment for heart failure alone.
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Frailty impacts outcomes in patients undergoing cardiac surgery and should be
identified in patients with advanced heart failure undergoing surgical options, especially
those undergoing LVAD. It is important to recognize those who are frail and those more
likely to benefit from LVAD and have positive outcomes. Recent studies have
demonstrated that patient selection is essential to ensure positive results with less adverse
events following LVAD implantation. However, in order to recognize those who will
most likely benefit, more research is needed to determine the best way to select these
candidates. Identifying those who are frail, is gaining interest for patient selection and
while frailty has been extensively studied in other populations, limited research has been
conducted in patients undergoing LVAD.
Chapter three is a data analysis on measures of frailty in patients with LVADs and
identifies measures of frailty in patients with heart failure scheduled for LVAD
implantation and which measures of frailty are predictive of 30 day readmissions. I
identify a subset of 23 patients with end stage heart failure enrolled in a study at a
university medical center. Baseline measures of Fried’s criteria (gait speed, exhaustion,
weight loss, strength, physical activity), albumin, 6 MWT, handgrip and SPBB were
entered into the model along with covariates identified from the literature (age, gender,
BMI, heart failure etiology, diabetes, coronary artery disease and chronic kidney disease).
Demographic and clinical characteristics were reported using frequencies and
percentages for categorical variables and mean ± standard deviation for continuous
variables. Frequencies were used to determine frailty for each measure. Chi-square
analysis was used to determine if the measures of frailty were predictive of 30 day
readmission. All analysis was conducted using SPSS software.
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The study concluded that none of the markers examined were good predictors of
frailty in patients with advanced heart failure with LVADs. The only marker that was
predictive of 30 day readmission rates was handgrip strength. This was a negative
association indicating that compared to not frail, frail patients by handgrip criteria were
93.4% less likely to be admitted. Over 85% of the patients were frail as measured by
Fried’s criteria, 6MWT, Low Physical Activity, Self-reported exhaustion, and albumin.
The other markers of frailty measured frailty in over 50% of the patients. These findings
indicate that these measures of frailty are not precise measurements of frailty and some
markers such as self-reported exhaustion may be overly sensitive to measuring frailty in
patients with LVADs.
The results from my study may be due to the fact that measures of frailty such as
Fried’s and SPPB that are devised of several components that may not accurately
identify frailty in patients with end stage heart failure with LVADs because some of
these components may be influenced by chronic disease. Chronic inflammation which is
associated with heart failure is also a linked to cognitive impairment which affects
physical performance measure such as gait speed which is a part of both the Fried’s and
SPBB criteria. In addition, our study did not recognize hand grip strength as a measure
of frailty, whereas other studies have found that hand grip strength is an independent
predictor of frailty. Our small sample size is likely the culprit to the difference in these
findings. In addition, discrepancies may be attributed to the degree of illness in the
cohort. Some patients were severely ill requiring more emergent LVAD implantation,
while others were stable at home and scheduled for LVAD implantation.
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Once measures of frailty have been identified, it is important to determine which
measures may improve over time after an intervention. Previous findings support that
those who have improvement in measures of frailty, have fewer complications and better
outcomes. To further expand on this concept, we examined which measures of frailty
improved over time after LVAD implantation.
Chapter Four is an analysis of albumin, 6MWT and handgrip and whether these
measures of frailty improve over 3 months. Longitudinal data was collected at baseline
(pre-implantation) and at 3 months (post-implantation). Data from 23 patients with HF
who underwent LVAD implantation was used in the analysis. Demographic and clinical
characteristics were reported using frequencies and percentages for categorical variables
and mean ± standard deviation for continuous variables. Frequencies were used to
determine frailty for each measure. Paired t-tests were used to determine differences
between pre- and post- 6MWT, handgrip strength, and serum albumin levels. McNemar’s
chi-square tests were used to compare proportions of individuals within each frailty
category from pre- to post-implantation. Results of the study demonstrated the 6MWT
and albumin improved post LVAD implantation at 3 months while handgrip strength did
not change.
Our findings on frailty measures that improve post-LVAD implantation are
consistent with prior studies who have examined improvement in 6MWT and albumin
levels prior and post implantation but differ from previous investigations regarding frailty
as defined by handgrip strength. Again, our small sample size likely contributes to the
difference in findings regarding handgrip strength. Also, longitudinal studies have the
ability to demonstrate progress and change over time. Chung et al found that handgrip
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was an independent predictor of frailty, but their study measured changes in handgrip
over 6 months. Additionally, Maurer et al reported that is took at least 3 months to start
seeing improvement in frailty with significant improvement at 6 months. We only
compared 2 time points which included baseline and 3 months post implantation. Based
on previous the previous finding, more long term follow-up is needed to identify
reversibility of frailty.
Impact of Dissertation on the State of Science
This dissertation represents an important contribution to the literature as little is
known about frailty in patients with LVADs. The findings of this dissertation filled some
gaps in understanding which measures of frailty including Fried’s criteria, SPPB,
albumin, 6MWT and handgrip strength measured frailty in patient with end stage HF
undergoing LVAD implantation and which measures of frailty predict 30 day
readmission. In addition, the findings support which measures of frailty improve post
LVAD implantation.
Fried’s criteria is the most commonly used frailty measure in patients with
LVADs and is highly predictive of adverse outcomes. Multidimensional frailty measures
such as Fried’s criteria, include multiple domains that may vary from one measure to
another and may be difficult to apply in certain settings and in patients that are severely
ill. Single item measures may be successful in measuring frailty and may be more
practical in patients with LVADs. While several studies have examined gait speed as a
single measure and a couple of studies have examined handgrip as a single measure,
other specific measures that can help identify frailty are unknown.
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In Chapter three, I evaluate if single measures of frailty and measurement tools
that utilize several components to measure frailty measure frailty in patients with LVADs
and if these markers of frailty predict 30 day readmission rates. No studies in the
literature evaluating frailty have examined all these tools and no studies have looked at
frailty measures that predict 30 day readmission rates. Prior studies have examined how
frailty impacts length of stay, time to extubation and adverse outcomes but the results are
inconsistent. Whether single objective measures of frailty are valid in determining frailty,
more research is needed but my study findings provide a strong beginning foundation.
Additionally, prior studies that measure frailty in older adults have demonstrated
that some measures of frailty can improve. Very few studies have examined this in
patients with LVADs. There are limited longitudinal studies examining the reversal of
frailty measures in patients receiving LVADs Improvement in frailty measures after 6
months has been examined by some investigators but specific measures that support
reversibility of frailty are unknown. Improvement in handgrip strength and gait speed
post LVAD implantation has been investigated. Additional measures of frailty in patients
with LVADs that support reversibility of frailty have not been examined.
The results described in chapter 4 advances the state of science in evaluating how
baseline measures of albumin, 6MWT and handgrip strength improve from baseline to 3
months. My study supports that albumin and 6MWT improved 3 months post LVAD.
While handgrip strength did not improve at 3 months, other investigators found that at 6
months, handgrip strength did improve and more long-term analysis should be considered
in future studies.
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Recommendations for future research
Frailty is an important predictor of adverse outcomes in patients with HF
undergoing LVAD such as 30 day readmission, increased hospital LOS, mortality and
post-operative complications. Frailty is more common in patients with chronic disease
such as those with end-stage heart failure. As a result, frailty should be routinely assessed
in patients with end stage heart failure approaching LVAD implantation to detect the
presence of frailty, need for early intervention to slow the progression and improve
outcomes and assist with patient selection for LVAD implantation.
In order to assess the presence of frailty, clinicians need to be able to use sound
measures that are easy to administer and brief without being burdensome to the patients.
There are tools available to measure frailty but some measures are lengthy and
burdensome making it difficult to complete. More studies need to be conducted in order
to replicate the results of this study and support the reliability in patients with HF
undergoing LVAD implantation. In addition, measurement tools with multiple
components may over diagnose frailty whereas single measures may be prone to missing
frailty. However, the underlying assumption would be that because components of the
pathologic process of frailty are associated with each other, not all are necessary to be
labeled as frail and single measures may be adequate. Addition research is needed to test
this assumption.
Heart failure is a dynamic illness and future research should focus on long-term
follow-up to determine how frailty impacts outcomes and which measures of frailty are
reversed following LVAD implantation. Patients with end-stage heart failure are often
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deconditioned, malnourished, and have a chronic inflammatory response. Due to their
condition they may not seek and utilize available resources appropriately such as
attending cardiac rehabilitation, nutrition counseling, or clinic appointments. As a result,
their condition further deteriorates and frailty is exacerbated. Focusing on earlier
identification of frailty in the ambulatory setting and early intervention for physical
rehabilitation and nutritional supplementation should also be a focus in this population to
slow the progression of frailty. A small randomized trial found that patients who were
enrolled in cardiac rehabilitation after LVAD implantation had promising results with
improvements in frailty. Additional research including longitudinal data are needed to
further support these findings.
Limitations
Limitations of these studies include that these were single-centered studies and
each of the studies reported in this dissertation had a small sample size. In addition,
patients with end stage heart failure who underwent LVAD implantation participated in
the study which limits heterogeneity. Additional potential limitations include the use of
self-reported measures of exhaustion and physical activity and in some patients selfreported weight loss in the past year. We did not have access to all patients’ information
from previous medical records to verify weight loss. Additionally, the fact that many of
these patients were very ill resulted in limitations of the applicability of some of the
frailty measures. The relatively short-term follow-up does not allow any conclusions to
be made about long-term outcomes and reversibility.
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There are barriers to engaging in some measures of frailty. Patients who have
marked physical limitations are unable to complete some measures such as 6 MWT and
previously reported gait speed test. Utilizing weight loss as a measure of frailty may
underestimate the prevalence of frailty in obese patients and it is also difficult to discern
true weight loss in patients with heart failure due to variability secondary to volume
status. Chronic inflammation associated with chronic disease is also associated with
cognitive impairment which is associated with a decline in psychomotor activities such as
gait speed. This may lead to inconsistencies with identifying those who are frail because
it is often difficult to differentiate between frailty and the effects of the disease itself.
Conclusion
In summary, implications of this dissertation include the importance of
monitoring frailty over time as well as the need for further longitudinal studies that
examine the relationships between frailty and early intervention to slow the progression
of frailty. A better understanding how frailty changes over time will allow clinicians the
opportunity for timely interventions designed to reduce the progression and improve
outcomes. In addition, identifying those that are frail will allow for better patient
selection to avoid unnecessary LVAD implantation on those likely to not survive or have
post-operative complications and adverse events and will identify markers of frailty that
will likely improve in patients post LVAD implantation.

Copyright © Candice Harvey Falls 2019
100

REFERENCES
1.
Afilalo, J. (2011). Frailty in patients with cardiovascular disease: why, when, and
how to measure. Current cardiovascular risk reports, 5(5), 467.
2.
Afilalo, J., Alexander, K. P., Mack, M. J., Maurer, M. S., Green, P., Allen, L. A.,
... & Forman, D. E. (2014). Frailty assessment in the cardiovascular care of older adults.
Journal of the American College of Cardiology, 63(8), 747-762.
3.
Aissaoui, N., Morshuis, M., Maoulida, H., Salem, J. E., Lebreton, G., Brunn, M.,
... & Latremouille, C. (2017). Management of end-stage heart failure patients with or
without ventricular assist device: an observational comparison of clinical and economic
outcomes. European Journal of Cardio-Thoracic Surgery, 53(1), 170-177.
4.
Akhter, S. A., Badami, A., Murray, M., Kohmoto, T., Lozonschi, L., Osaki, S., &
Lushaj, E. B. (2015). Hospital readmissions after continuous-flow left ventricular assist
device implantation: incidence, causes, and cost analysis. The Annals of thoracic surgery,
100(3), 884-889.
5.
Arques, S., Roux, E., Stolidi, P., Gelisse, R., & Ambrosi, P. (2011). Usefulness of
serum albumin and serum total cholesterol in the prediction of hospital death in older
patients with severe, acute heart failure. Archives of cardiovascular diseases, 104(10),
502-508.
6.
Bensimhon, D, Adams, G, Whellan, D, et al. Effect of exercise training on
ventricular function, dyssynchrony, resting myocardial perfusion, and clinical outcomes
in patients with heart failure: A nuclear ancillary study of Heart Failure and A Controlled
Trial Investigating Outcomes of Exercise TraiNing (HF-Action); design and rationale.
Am Heart J. 2007; 154:46-53.
7.
Bergman, H., Ferrucci, L., Guralnik, J., Hogan, D. B., Hummel, S.,
Karunananthan, S., & Wolfson, C. (2007). Frailty: an emerging research and clinical
paradigm—issues and controversies. The Journals of Gerontology Series A: Biological
Sciences and Medical Sciences, 62(7), 731-737.
8.
Bortz, W. M. (2002). A conceptual framework of frailty: a review. The Journals
of Gerontology Series A: Biological Sciences and Medical Sciences, 57(5), M283-M288.
9.
Boxer, R. S., Dauser, D. A., Walsh, S. J., Hager, W. D., & Kenny, A. M. (2008).
The Association between vitamin D and Inflammation with the 6‐minute walk and frailty
in patients with heart failure. Journal of the American Geriatrics Society, 56(3), 454-461.
10.
Boxer, R., Kleppinger, A., Ahmad, A., Annis, K., Hager, D., & Kenny, A. (2010).
The 6‐minute walk is associated with frailty and predicts mortality in older adults with
heart failure. Congestive Heart Failure, 16(5), 208-213.
11.
Boxer, R. S., Shah, K. B., & Kenny, A. M. (2014). Frailty and prognosis in
advanced heart failure. Current opinion in supportive and palliative care, 8(1), 25-29.
12.
Boummel, R, Rijnsoever, E, Borleffs, J, et al. Effect of cardiac resynchronization
therapy in patients with New York Heart Association function class IV heart failure. Am
J Cardiol. 2010; 106:1146-1151.
13.
Buck, H. G., & Riegel, B. (2011). The impact of frailty on health related quality
of life in heart failure. European Journal of Cardiovascular Nursing, 10(3), 159-166.
14.
Buggey, J., Mentz, R. J., & Galanos, A. N. (2015). End-of-life heart failure care
in the United States. Heart failure clinics, 11(4), 615-623.
101

15.
Bui, A. L., Horwich, T. B., & Fonarow, G. C. (2011). Epidemiology and risk
profile of heart failure. Nature Reviews Cardiology, 8(1), 30.
16.
Burkhoff D, Sayer G, Doshi D, Uriel N. (2015) Hemodynamics of Mechanical
Circulatory Support. J Am Coll Cardiol 66: 2664-2674.
17.
Butler, J., Howser, R., Portner, P. M., & Pierson, R. N. (2005). Body mass index
and outcomes after left ventricular assist device placement. The Annals of thoracic
surgery, 79(1), 66-73.
18.
Cacciatore, F., Abete, P., Mazzella, F., Viati, L., Della Morte, D., D’Ambrosio,
D., ... & Ferrara, N. (2005). Frailty predicts long‐term mortality in elderly subjects with
chronic heart failure. European journal of clinical investigation, 35(12), 723-730.
19.
Cagliostro, B., Levin, A. P., Fried, J., Stewart, S., Parkis, G., Mody, K. P., ... &
Jorde, U. P. (2016). Continuous-flow left ventricular assist devices and usefulness of a
standardized strategy to reduce drive-line infections. The Journal of Heart and Lung
Transplantation, 35(1), 108-114.
20.
Casida, J. M., Marcuccilli, L., Peters, R. M., & Wright, S. (2011). Lifestyle
adjustments of adults with long-term implantable left ventricular assist devices: a
phenomenologic inquiry. Heart & Lung: The Journal of Acute and Critical Care, 40(6),
511-520.
21.
Chiarantini, D., Volpato, S., Sioulis, F., Bartalucci, F., Del Bianco, L., Mangani,
I., ... & Di Bari, M. (2010). Lower extremity performance measures predict long-term
prognosis in older patients hospitalized for heart failure. Journal of cardiac failure, 16(5),
390-395.
22.
Cheng, A., Williamitis, C. A., & Slaughter, M. S. (2014). Comparison of
continuous-flow and pulsatile-flow left ventricular assist devices: is there an advantage to
pulsatility?. Annals of cardiothoracic surgery, 3(6), 573.
23.
Chung, C, Wu, C, Jones, M, Kato, T, Dam, T, Givens, R, et al. Reduced handgrip
strength as a marker of frailty predicts clinical outcomes in patients with heart failure
undergoing ventricular assist device placement. J Cardiac Failure. 2014; doi:
10.1016/j.cardfail.2013.02.008
24.
Collins, S. P., Thorn, M., Nowak, R. M., Levy, P. D., Fermann, G. J., Hiestand, B.
C., ... & Pang, P. S. (2017). Feasibility of Serial 6-min Walk Tests in Patients with Acute
Heart Failure. Journal of clinical medicine, 6(9), 84.
25.
Cook, J. A., Shah, K. B., Quader, M. A., Cooke, R. H., Kasirajan, V., Rao, K. K.,
... & Tang, D. G. (2015). The total artificial heart. Journal of thoracic disease, 7(12),
2172.
26.
Cooper, L. B., Hammill, B. G., Allen, L. A., Lindenfeld, J., Mentz, R. J., Rogers,
J. G., ... & Hernandez, A. F. (2017). Assessing Frailty in Patients Undergoing Destination
Therapy Left Ventricular Assist Device: Observations from Interagency Registry for
Mechanically Assisted Circulatory Support. ASAIO journal (American Society for
Artificial Internal Organs: 1992).
27.
Copeland JG, Smith RG, Arabia FA, et al. Cardiac replacement with a total
artificial heart as a bridge to transplantation. N Engl J Med. 2004;351:859–67.
28.
Corti, M. C., Guralnik, J. M., Salive, M. E., & Sorkin, J. D. (1994). Serum
albumin level and physical disability as predictors of mortality in older persons. Jama,
272(13), 1036-1042.

102

29.
Coyle, L. A., Ising, M. S., Gallagher, C., Bhat, G., Kurien, S., Sobieski, M. A., &
Slaughter, M. S. (2010). Destination Therapy: One‐Year Outcomes in Patients With a
Body Mass Index Greater Than 30. Artificial organs, 34(2), 93-97.
30.
DeBakey ME: Left ventricular bypass pump for cardiac assistance. Clinical
experience. Am J Cardiol 1971, 27:3–11.
31.
Dobbels, F, Mauthner, O, Milisen, K. Frailty in left ventricular assist device
destination therapy: Putting a new motor in a rickety old car running out of gas? J. Heart
and Lung Transplant, 2014; 33(4): 347-349.
32.
Draper, K. V., Huang, R. J., & Gerson, L. B. (2014). GI bleeding in patients with
continuous-flow left ventricular assist devices: a systematic review and meta-analysis.
Gastrointestinal endoscopy, 80(3), 435-446.
33.
Dunlay, S, Park, S, Joyce, L, Daly, R, Stulak, J, McNallan, S, et al. Frailty and
outcomes after implant of left ventricular assist device as destination therapy. J. Heart
and Lung, 2014; 33(4): 359-365.
34.
Dzau V.J., Colucci W.S., Hollenberg N.K., Williams G.H. (1981) Relation of the
renin-angiotensin-aldosterone system to clinical state in congestive heart failure.
Circulation 63:645–651.
35.
Ellenbogen, K, Kay, G, Wilkoff, B. Device Therapy for Congestive Heart Failure.
Philadelphia PA. Elsevier Inc; 2004:1-45.
36.
Engelman, D. T., Adams, D. H., Byrne, J. G., Aranki, S. F., Collins, J. J., Couper,
G. S., ... & Rizzo, R. J. (1999). Impact of body mass index and albumin on morbidity and
mortality after cardiac surgery. The Journal of Thoracic and Cardiovascular Surgery,
118(5), 866-873.
37.
Fan, K., Wong, M., Cheng, K., Chow, C., & Leung, K. L. (2017, May). Frailty
conferred incremental prognostic significance in Chinese heart failure patients with
advanced heart failure. In European Journal of Heart Failure (Vol. 19, pp. 416-416). 111
River St, Hoboken 07030-5774, NJ USA: Wiley.
38.
Fiatarone, M. A., O'Neill, E. F., Ryan, N. D., Clements, K. M., Solares, G. R.,
Nelson, M. E., ... & Evans, W. J. (1994). Exercise training and nutritional
supplementation for physical frailty in very elderly people. New England Journal of
Medicine, 330(25), 1769-1775.
39.
Flint, K, Allen, L. Getting a grip on frailty: handgrip strength in patient selection
for left ventricular assist device. J. Cardiac Failure, 2014; doi
10.1016/j.cardfail.2014.03.002
40.
Flint, K, Matlock, D, Lindenfield, J, Allen, L. Frailty and the selection of patients
for destination therapy left ventricular assist device. Circulation Heart Failure. 2012;
5:286-293.
41.
Flint, K, Matlock, D, Sundareswaran, K, Lindenfield, J, Spertus, J, Farrar, D, et
al. Pre-operative health status and outcomes after continuous flow left ventricular assist
device implantation. J Heart and Lung Transplant, 2013; 32(12):1249-1254.
42.
Frazier OH, Akutsu T, Cooley DA. Total Artificial Heart (TAH) utilization in
man. Trans Am Soc Artif Intern Organs. 1982;28:534–8.
43.
Frazier OH, Bricker JT, Macris MP, Cooley DA. Use of a left ventricular assist
device as a bridge to transplantation in a pediatric patient. Tex Heart Inst J. 1989;16:46–
50

103

44.
Fried, L. P., Tangen, C. M., Walston, J., Newman, A. B., Hirsch, C., Gottdiener,
J., ... & McBurnie, M. A. (2001). Frailty in older adults: evidence for a phenotype. The
Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 56(3),
M146-M157.
45.
Gibbs, J., Cull, W., Henderson, W., Daley, J., Hur, K., & Khuri, S. F. (1999).
Preoperative serum albumin level as a predictor of operative mortality and morbidity:
results from the National VA Surgical Risk Study. Archives of surgery, 134(1), 36-42.
46.
Go, P. H., Hodari, A., Nemeh, H. W., Borgi, J., Lanfear, D. E., Williams, C. T., ...
& Morgan, J. A. (2015). Effect of preoperative albumin levels on outcomes in patients
undergoing left ventricular device implantation. ASAIO Journal, 61(6), 734-737.
47.
Gopal, D. J., Hanff, T. C., Mazurek, J. A., Grandin, W. E., Howard, J., FordeMcLean, R., ... & Jessup, M. (2017). Prognostic implications of changes in albumin
following left ventricular assist device implantation in patients with severe heart failure.
The American journal of cardiology, 120(11), 2003-2007.
48.
Grodin, J. L., Lala, A., Stevens, S. R., DeVore, A. D., Cooper, L. B.,
AbouEzzeddine, O. F., ... & Vader, J. M. (2016). Clinical implications of serum albumin
levels in acute heart failure: insights from DOSE-AHF and ROSE-AHF. Journal of
cardiac failure, 22(11), 884-890.
49.
Guaraldi, G., Malagoli, A., Theou, O., Brothers, T. D., Wallace, L. M. K., Torelli,
R., ... & Rockwood, K. (2017). Correlates of frailty phenotype and frailty index and their
associations with clinical outcomes. HIV medicine, 18(10), 764-771.
50.
Guvenc, T. S., Güzelburc, O., Ekmekci, A., Erdogan, S. B., Guvenc, R. C.,
Velibey, Y., ... & Eren, M. (2017). The Effect of Left Ventricular Assist Device
Implantation on Serum Albumin, Total Protein and Body Mass: A Short-Term,
Longitudinal Follow-Up Study. Heart, Lung and Circulation, 26(7), 702-708.
51.
Habal, M. V., & Garan, A. R. (2017). Long-term management of end-stage heart
failure. Best Practice & Research Clinical Anaesthesiology, 31(2), 153-166.
52.
Hasin, T., Marmor, Y., Kremers, W., Topilsky, Y., Severson, C. J., Schirger, J.
A., ... & Edwards, B. S. (2013). Readmissions after implantation of axial flow left
ventricular assist device. Journal of the American College of Cardiology, 61(2), 153-163.
53.
Hasin, T., Topilsky, Y., Kremers, W. K., Boilson, B. A., Schirger, J. A., Edwards,
B. S., ... & Daly, R. (2012). Usefulness of the six-minute walk test after continuous axial
flow left ventricular device implantation to predict survival. The American journal of
cardiology, 110(9), 1322-1328.
54.
Heberton, G. A., Nassif, M., Bierhals, A., Novak, E., LaRue, S. J., Lima, B., ... &
Joseph, S. M. (2016). Usefulness of psoas muscle area determined by computed
tomography to predict mortality or prolonged length of hospital stay in patients
undergoing left ventricular assist device implantation. The American journal of
cardiology, 118(9), 1363-1367.
55.
Ho, K. K., Pinsky, J. L., Kannel, W. B., & Levy, D. (1993). The epidemiology of
heart failure: the Framingham Study. Journal of the American College of Cardiology,
22(4 Supplement 1), A6-A13.

104

56.
Holdy, K., Dembitsky, W., Eaton, L. L., Chillcott, S., Stahovich, M., Rasmusson,
B., & Pagani, F. (2005). Nutrition assessment and management of left ventricular assist
device patients. The Journal of heart and lung transplantation, 24(10), 1690-1696.
57.
Holman, W. L., Naftel, D. C., Eckert, C. E., Kormos, R. L., Goldstein, D. J., &
Kirklin, J. K. (2013). Durability of left ventricular assist devices: Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011. The Journal of
thoracic and cardiovascular surgery, 146(2), 437-441.
58.
Imamura, T., Kinugawa, K., Nitta, D., Inaba, T., Maki, H., Hatano, M., ... & Ono,
M. (2015). Readmission due to driveline infection can be predicted by new score by
using serum albumin and body mass index during long-term left ventricular assist device
support. Journal of Artificial Organs, 18(2), 120-127.
59.
Iyengar, A., Kwon, O. J., Tamrat, M., Salimbangon, A., Satou, N., Benharash, P.,
... & Kwon, M. H. (2017). The In-Hospital Cost of Ventricular Assist Device Therapy:
Implications for Patient Selection. Asaio Journal, 63(6), 725-730.
60.
Jha, S. R., Hannu, M. K., Newton, P. J., Wilhelm, K., Hayward, C. S., Jabbour,
A., ... & Connellan, M. (2017). Reversibility of frailty after bridge-to-transplant
ventricular assist device implantation or heart transplantation. Transplantation Direct,
3(7).
61.
Joseph, S. M., Manghelli, J. L., Vader, J. M., Keeney, T., Novak, E. L., Felius, J.,
... & Rich, M. W. (2017). Prospective assessment of frailty using the Fried criteria in
patients undergoing left ventricular assist device therapy. American Journal of
Cardiology, 120(8), 1349-1354.
62.
Kannel, W. B., & Belanger, A. J. (1991). Epidemiology of heart failure. American
heart journal, 121(3), 951-957.
63.
Kannel, W. B. (2000). Incidence and epidemiology of heart failure. Heart failure
reviews, 5(2), 167-173.
64.
Kato, T. S., Kitada, S., Yang, J., Wu, C., Takayama, H., Naka, Y., ... & Schulze,
P. C. (2013). Relation of preoperative serum albumin levels to survival in patients
undergoing left ventricular assist device implantation. The American journal of
cardiology, 112(9), 1484-1488.
65.
Kenny, T. The nuts and bolts of cardiac resynchronization therapy. Malden, MA.
Blackwell Futura. 2007; 1-62.
66.
Khan, H., Kalogeropoulos, A. P., Georgiopoulou, V. V., Newman, A. B., Harris,
T. B., Rodondi, N., ... & Butler, J. (2013). Frailty and risk for heart failure in older adults:
the health, aging, and body composition study. American heart journal, 166(5), 887-894.
67.
Kirklin, J. K., & Naftel, D. C. (2008). Mechanical circulatory support: registering
a therapy in evolution. Circulation: Heart Failure, 1(3), 200-205.
68.
Kirklin, J. K., Pagani, F. D., Kormos, R. L., Stevenson, L. W., Blume, E. D.,
Myers, S. L., ... & Naftel, D. C. (2017). Eighth annual INTERMACS report: special
focus on framing the impact of adverse events. The Journal of Heart and Lung
Transplantation, 36(10), 1080-1086.
69.
Klabunde RE. (2012) Cardiovascular Physiology Concepts. 2nd ed.
70.
Kron, J, Conti, J. Cardiac resynchronization therapy for treatment of heart failure
in the elderly. Clin Geriatr Med. 2007; 23:193-203.

105

71.
Kushnir, V. M., Sharma, S., Ewald, G. A., Seccombe, J., Novak, E., Wang, I. W.,
... & Gyawali, C. P. (2012). Evaluation of GI bleeding after implantation of left
ventricular assist device. Gastrointestinal endoscopy, 75(5), 973-979.
72.
Lee, D. H., Buth, K. J., Martin, B. J., Yip, A. M., & Hirsch, G. M. (2010). Frail
patients are at increased risk for mortality and prolonged institutional care after cardiac
surgery. Circulation, 121(8), 973-978.
73.
Liljeroos M, Agren S, Jaarsma T, Arestedt K, Stromberg A. Long Term FollowUp after a Randomized Integrated Educational and Psychosocial Intervention in PatientPartner Dyads Affected by Heart Failure. PloS one2015; 10(9): e0138058
74.
Lim, H. S., Howell, N., & Ranasinghe, A. (2017). The physiology of continuousflow left ventricular assist devices. Journal of cardiac failure, 23(2), 169-180.
75.
Long, E, Swain, G, Mangi, A. Comparative survival and cost effectiveness of
advanced therapies for end-stage heart failure. Circulation Heart Failure 2014; 7:470-478.
76.
Lund LH, Edwards LB, Dipchand AI, et al. The registry of the International
Society for Heart and Lung Transplantation: thirty-third adult heart transplantation
report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung
Transplant 2016;35: 1158–69.
77.
Lund, LH, Khush KK, Wia MAS, et al. The Registry of the International Society
for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report—
2017. The Journal of Heart and Lung Transplantation, Vol 36, No 10, October 2017; with
permission. (Figure 8 in original)
78.
Manghelli, J., Vader, J., Keeney, T., Martinez, S., Patel, J., Novak, E., ... &
Joseph, S. M. (2014). Frailty Is Associated With Increased Time on Ventilator in Patients
Undergoing Left Ventricular Assist Device Implantation: A Prospective Study. The
Journal of Heart and Lung Transplantation, 33(4), S36.
79.
Mangi, A. A. (2011). Right ventricular dysfunction in patients undergoing left
ventricular assist device implantation: predictors, management, and device utilization.
Cardiology clinics, 29(4), 629-637.
80.
Martin, S. I., Wellington, L., Stevenson, K. B., Mangino, J. E., Sai-Sudhakar, C.
B., Firstenberg, M. S., ... & Sun, B. C. (2010). Effect of body mass index and device type
on infection in left ventricular assist device support beyond 30 days. Interactive
cardiovascular and thoracic surgery, 11(1), 20-23.
81.
Masip, J., Formiga, F., Fernández-Castañer, M., Fernández, P., Comín-Colet, J.,
& Corbella, X. (2018). First hospital admission due to heart failure: In-hospital mortality
and patient profile. Revista clinica espanola. 219(3), 130-140.
82.
Maurer, M. S., Horn, E., Reyentovich, A., Dickson, V. V., Pinney, S., Goldwater,
D., ... & Helmke, S. (2017). Can a Left Ventricular Assist Device in Individuals with
Advanced Systolic Heart Failure Improve or Reverse Frailty?. Journal of the American
Geriatrics Society, 65(11), 2383-2390.
83.
McMurray, J. J., & Stewart, S. (2000). Epidemiology, aetiology, and prognosis of
heart failure. Heart, 83(5), 596-602.
84.
Mehra, M. R., Canter, C. E., Hannan, M. M., Semigran, M. J., Uber, P. A., Baran,
D. A., ... & Lund, L. H. (2016). The 2016 International Society for Heart Lung
Transplantation listing criteria for heart transplantation: a 10-year update. The Journal of
Heart and Lung Transplantation, 35(1), 1-23.

106

85.
Mishra, V., Fiane, A. E., Geiran, O., Sørensen, G., Khushi, I., & Hagen, T. P.
(2012). Hospital costs fell as numbers of LVADs were increasing: experiences from Oslo
University Hospital. Journal of cardiothoracic surgery, 7(1), 76.
86.
Miller, L. W., & Guglin, M. (2013). Patient selection for ventricular assist
devices: a moving target. Journal of the American College of Cardiology, 61(12), 12091221.
87.
Mitter, S. S., & Yancy, C. W. (2017). Contemporary approaches to patients with
heart failure. Cardiology clinics, 35(2), 261-271.
88.
Morris, R. J. (2012). The Syncardia Total Artificial Heart: Implantation
Technique. Operative Techniques in Thoracic and Cardiovascular Surgery, 17(2); 164
with permission (Figure 9, panels B and C).
89.
Mosterd, A., & Hoes, A. W. (2007). Clinical epidemiology of heart failure. Heart,
93(9), 1137-1146.
90.
Murad, K., & Kitzman, D. W. (2012). Frailty and multiple comorbidities in the
elderly patient with heart failure: implications for management. Heart failure reviews,
17(4-5), 581-588.
91.
Nieminen, M. S., Dickstein, K., Fonseca, C., Serrano, J. M., Parissis, J., Fedele,
F., ... & Brito, D. (2015). The patient perspective: quality of life in advanced heart failure
with frequent hospitalisations. International journal of cardiology, 191, 256-264.
92.
Nishi, I., Seo, Y., Hamada-Harimura, Y., Sato, K., Sai, S., Yamamoto, M., ... &
Suzuki, S. (2018). Utility of nutritional screening in predicting short-term prognosis of
heart failure patients. International heart journal, 59(2), 354-360.
93.
O'Horo, J. C., Abu, O. S., Stulak, J. M., Wilhelm, M. P., Baddour, L. M., &
Sohail, M. R. (2017). Left Ventricular Assist Device Infections: A Systematic Review.
ASAIO journal (American Society for Artificial Internal Organs: 1992).
94.
Okumura N., Jhund P.S., Gong J., et al., PARADIGM-HF Investigators and
Committees (2016) Importance of clinical worsening of heart failure treated in the
outpatient setting: evidence from the Prospective Comparison of ARNI With ACEI to
Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
(PARADIGM-HF). Circulation 133:2254–2262.
95.
Packer M. (1992) The neurohormonal hypothesis: a theory to explain the
mechanism of disease progression in heart failure. J Am Coll Cardiol 20:248–254.
96.
Petrovic, M., Nathan, S., Radovancevic, R., Rajapreyar, I., Dasher, K. J., Akay,
M. H., ... & Gregoric, I. D. (2016). Adverse Events in Continuous-Flow LVAD
Recipients: Gastrointestinal Bleeding is Still Notable?. The VAD Journal, 2(1), 23.
97.
Pfuntner, A., Wier, L. M., & Stocks, C. (2006). Most frequent conditions in US
hospitals, 2011: statistical brief# 162.
98.
Pritchard, J. M., Kennedy, C. C., Karampatos, S., Ioannidis, G., Misiaszek, B.,
Marr, S., ... & Papaioannou, A. (2017). Measuring frailty in clinical practice: a
comparison of physical frailty assessment methods in a geriatric out-patient clinic. BMC
geriatrics, 17(1), 264.
99.
Pruser, J. L., Kuchibhatla, M. N., Fillenbaum, G. G., Harding, T., Peterson, E. D.,
& Alexander, K. P. (2006). Identifying frailty in hospitalized older adults with significant
coronary artery disease. Journal of the American Geriatrics Society, 54(11), 1674-1681.

107

100. Pulikottil-Jacob, R, Suri, G, Connock, M, Kandala, N, Sutcliffe, P, Maheswaran,
H, et al. Comparative cost-effectiveness of the HeartWare versus HeartMate II left
ventricular assist devices used in the United Kindgom National Health Service bridge-totransplant program for patients with heart failure. J Heart and Lung Transplant, 2014;
33(4):350-358.
101. Rapp-Kesek, D., Ståhle, E., & Karlsson, T. (2004). Body mass index and albumin
in the preoperative evaluation of cardiac surgery patients. Clinical nutrition, 23(6), 13981404.
102. Raymond, A. L., Kfoury, A. G., Bishop, C. J., Davis, E. S., Goebel, K. M.,
Stoker, S., ... & Alharethi, R. (2010). Obesity and left ventricular assist device driveline
exit site infection. ASAIO Journal, 56(1), 57-60.
103. Rennyson, S. L., Shah, K. B., Tang, D. G., Kasirajan, V., Pedram, S., Cahoon,
W., & Malhotra, R. (2013). Octreotide for Left Ventricular Assist Device–Related
Gastrointestinal Hemorrhage: Can We Stop The Bleeding?. Asaio Journal, 59(4), 450451.
104. Roger, V, Go, A, Lloyd-Jones, D, et al. Heart Disease and Stroke Statistics 2012
Update: A reports from the American Heart Association. Circulation. 2011; 112-115.
105. Rogers, J. G., Butler, J., Lansman, S. L., Gass, A., Portner, P. M., Pasque, M. K.,
... & INTrEPID Investigators. (2007). Chronic mechanical circulatory support for
inotrope-dependent heart failure patients who are not transplant candidates: results of the
INTrEPID Trial. Journal of the American College of Cardiology, 50(8), 741-747.
106. Rose, E. A., Moskowitz, A. J., Packer, M., Sollano, J. A., Williams, D. L.,
Tierney, A. R., ... & Weinberg, A. D. (1999). The REMATCH trial: rationale, design, and
end points. The Annals of thoracic surgery, 67(3), 723-730.
107. Searle, S. D., Mitnitski, A., Gahbauer, E. A., Gill, T. M., & Rockwood, K. (2008).
A standard procedure for creating a frailty index. BMC geriatrics, 8(1), 24.
108. Slaughter, M. S., Rogers, J. G., Milano, C. A., Russell, S. D., Conte, J. V.,
Feldman, D., ... & Wozniak, T. C. (2009). Advanced heart failure treated with
continuous-flow left ventricular assist device. New England Journal of Medicine,
361(23), 2241-2251.
109. Stolf NAG. (2017) History of Heart Transplantation: a Hard and Glorious
Journey. Braz J Cardiovasc Surg;32(5):423-7.
110. Studenski, S., Perera, S., Patel, K., Rosano, C., Faulkner, K., Inzitari, M., ... &
Nevitt, M. (2011). Gait speed and survival in older adults. Jama, 305(1), 50-58.
111. Stulak, J. M., Davis, M. E., Haglund, N., Dunlay, S., Cowger, J., Shah, P., ... &
Maltais, S. (2016). Adverse events in contemporary continuous-flow left ventricular
assist devices: A multi-institutional comparison shows significant differences. The
Journal of thoracic and cardiovascular surgery, 151(1), 177-189.
112. Sundararajan, S., Kiernan, M. S., DeNofrio, D., & Vest, A. R. (2016). Cachexia Is
Common in Ventricular Assist Device Recipients but Not Predictive Of Mortality.
Journal of Cardiac Failure, 22(8), S57-S58.
113. Szygula-Jurkiewicz, B., Szczurek, W., Skrzypek, M., Zakliczyński, M., Siedlecki,
Ł., Przybyłowski, P., ... & Gąsior, M. (2017). One-year survival of ambulatory patients
with end-stage heart failure: the analysis of prognostic factors. Pol Arch Intern Med, 127,
254-260.

108

114. Tabue-Teguo, M., Dartigues, J. F., Simo, N., Kuate-Tegueu, C., Vellas, B., &
Cesari, M. (2018). Physical status and frailty index in nursing home residents: results
from the INCUR study. Archives of gerontology and geriatrics, 74, 72-76.
115. Today, C. S. Heart Pump Progress Announced-A promising step in artificial heart
technology. Children's Today (March), 1(5).
116. Tse, G., Gong, M., Wong, S. H., Wu, W. K., Bazoukis, G., Lampropoulos, K., ...
& Woo, J. (2018). Frailty and Clinical Outcomes in Advanced Heart Failure Patients
Undergoing Left Ventricular Assist Device Implantation: A Systematic Review and
Meta-analysis. Journal of the American Medical Directors Association. Journal of the
American Medical Directors Association, 19(3), 255-261.
117. Uchmanowicz, I., Kuśnierz, M., Wleklik, M., Jankowska-Polańska, B., Jaroch, J.,
& Łoboz-Grudzień, K. (2017). Frailty syndrome and rehospitalizations in elderly heart
failure patients. Aging Clinical and Experimental Research, 1-7.
118. Whellan, D, O’Connor, C, Lee, K, et al. Heart failure and a controlled trial
investigating outcomes of exercise training: Design and rationale. Am Heart J. 2007;
153:201-211failure patients. Aging Clinical and Experimental Research, 1-7.
119. Wozniak, C, Stehlik, J, Bradley, C, Baird, C, McKellar, S, Song, H, et al.
Ventricular Assist Devices or Inotropic Agents in Status 1A Patients? Survival Analysis
of the United Network of Organ Sharing Database. Ann Thorac Surg 2014; 97:1364-72.
120. Xue, Q. L. (2011). The frailty syndrome: definition and natural history. Clinics in
geriatric medicine, 27(1), 1-15.
121. Yancey, C.W., Jessup M., Bozhurt B., et al: 2013 ACCF/AHA guideline for
management of heart failure. J Am Coll Cardiol 2013: 62: pp.e147-3239.
122. Yancy C.W., Jessup M., Bozkurt B., et al. (2016) 2016 ACCF/AHA/HFSA
focused update on new pharmacological therapy for heart failure: an update of the 2013
ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol 68:1476–
1488.
123. Yost, G., & Bhat, G. (2017). Relationship between handgrip strength and length
of stay for left ventricular assist device implantation. Nutrition in Clinical Practice,
32(1), 98-102.
124. Zielińska, D., Bellwon, J., Rynkiewicz, A., & Elkady, M. A. (2013). Prognostic
value of the six-minute walk test in heart failure patients undergoing cardiac surgery: a
literature review. Rehabilitation research and practice, 2013.
125. Zile MR, Bennett TD, St John Sutton M, et al. (2008) Transition from chronic
compensated to acute decompensated heart failure: pathophysiological insights obtained
from continuous monitoring of intracardiac pressures. Circulation;118:1433–41.

109

Candice Harvey Falls, ACNP-BC, CVNP-BC

Education
University of Kentucky BA 2001, Exercise Science
University of Kentucky MS 2003, Exercise Physiology
Vanderbilt University MSN 2004, Nursing

Professional Experience
Dates

Institution and Location

Clinical Position

November 2013 – Present

University of Kentucky Hospital
Lexington, KY

Acute Care Nurse
Practitioner/Supervisor
Cardiology

June 2010 – August 2013

Graves Gilbert Clinic
Bowling Green, KY

Acute Care Nurse
Practitioner
Cardiology

August 2009 – April 2010

Sahetya Medical Group
Bowling Green, KY

Acute Care Nurse
Practitioner
Critical Care/Pulmonary

November 2007 – July 2009

Paragon Family Practice
Lexington, KY

Acute Care Nurse
Practitioner
Internal Medicine

June 2008 – December 2008

Cardiology Associates
Lexington, KY

Acute Care Nurse
Practitioner
Cardiology

December 2006 – May 2008

Total Med
Lexington, KY

Acute Care Nurse
Practitioner
Medical Weight loss

October 2005 – December
2006

Nashville General Hospital
Nashville, TN

Registered Nurse
Emergency Room

September 2004 – October
2005

Vanderbilt University Hospital
Nashville, TN

Registered Nurse
Emergency Room

June 2003 – August 2004

Lifeline Home Health
Bowling Green, KY

Physician/Community
Educator

January 2002 – May 2003

University of Kentucky
Lexington, KY

Teaching Assistant
Kinesiology

110

Professional Experience, continued
Dates

Institution and Location

Academic Position

January 2007 – June 2009

University of Kentucky College
of Nursing
Lexington, KY

Pre-Doctoral
Fellowship

Awards and Honors
Cal Turner Leadership Recipient, 2006
Vanderbilt University Nursing Scholarship, 2005 – 2006

Publications
*Falls, Candice, Kolodziej, Andrew (2019). Surgical Approaches in Heart Failure. Critical Care
Nursing Clinics 907, Volume 31, Issue 3

111

